Chapter 31 · Chapter 31 REFERENCES 1. Guyton AC. ... 33.Vary TC. Increased pyruvate ......

Chapter 31

REFERENCES

1. Guyton AC. Determinants of cardiac output by equating venous return curves with cardiac output curves. Physiol Rev. 1955;35:123-129.

2. Goldberg HS, Rabson J. Control of the cardiac output by the systemic vessels. Am J Cardiol. 1981;47:696-702.

3. Sarnoff SJ. Myocardial contractility as described by ventricular function curves: observations on Starling’s law of the heart. Physiol Rev. 1955;35:107.

4. Kramer A, Zygun D, Hawes H, Easton P, Ferland A. Pulse pres-sure variation predicts fluid responsiveness following coronary artery bypass surgery. Chest. 2004;126:1563-1568.

5. Prewitt RM, Wood LDH. The effect of positive end-expira-tory pressure on ventricular function in dogs. Am J Physiol. 1979;45:H534.

6. Prewitt RM, Oppenheimer L, Sutherland JB, Wood LDH. The effects of positive end-expiratory pressure on left ventricular mechanics in patients with hypoxemic respiratory failure. Anesthesiology. 1981;55:409.

7. Spencer KT, Lang RM. Diastolic heart failure. Postgrad Med. 1997;101:63.

8. Taylor RR, Coveld JW, Sonnenblick EH, Ross J. Dependence of ventricular distensibility on filling of the opposite ventricle. Am J Physiol. 1967;213:711.

9. Craven KD, Wood LDH. Extrapericardial and esophageal pressures with positive end expiratory pressure in dogs. J Appl Physiol. 1981;51:798.

10. Pinsky MR, Desmet J-M, Vincent J. Effect of positive endexpira-tory pressure on right ventricular function in humans. Am Rev Respir Dis. 1992;146:681.

11. Tivoni D. Effect of transient ischemia on left ventricular func-tion and prognosis. Eur Heart J. 1993;14(suppl A):2-7.

12. Sagawa K. End-systolic pressure-volume relationship in retro-spect and prospect. Fed Proc. 1984;43:2399.

13. Kass DA, Maughn WL, Guo ZM, et al. Comparative influence of load versus inotropic states on indices of ventricular contrac-tility. Circulation. 1987;76:1422.

14. Walley KR, Becker CJ, Hogan RA, et al. Progressive hypoxemia limits left ventricular oxygen consumption and contractility. Circ Res. 1988;63:849.

15. Walley KR, Lewis TH, Wood LDH. Acute respiratory acidosis decreases left ventricular contractility but increases cardiac output. Circ Res. 1990;67:628.

16. Carroll JD, Lang RM, Neuman AL, et al. The differential effects of positive inotropic and vasodilator therapy on diastolic prop-erties in patients with congestive cardiomyopathy. Circulation. 1985;74:815.

17. Prewitt RM, Wood LDH. Effects of altered resistive load on left ventricular systolic mechanics in dogs. Anesthesiology. 1982;56:195.

18. Chadda K, Annane D, Hart N, et.al. Cardiac and respiratory effects of continuous positive airway pressure and noninvasive ventilation in acute cardiac pulmonary edema. Crit Care Med. 2002;30:2457.

19. Mitzner W, Goldberg HS. Effects of epinephrine on resistive and compliant properties of the canine vasculature. J Appl Physiol. 1975;39:272.

20. Mitzner W, Goldberg HS, Lichtenstein S. Effect of thoracic blood volume changes on steady state cardiac output. Circ Res. 1976;38:255.

21. Brengelmann G. A critical analysis of the view that right atrial pres-sure determines venous return. J Appl Physio. 2003;94:849-859.

22. Magder S Point: the classical Guyton view that mean systemic pressure, right atrial pressure, and venous resistance govern venous return is/is not correct. J. Appl Physiol. 2006;101: 1523-1525.

23. Guyton AC, Sagawa K. Compensations of cardiac output and other circulatory function in a reflexic dogs with large A-V fistulas. Am J. Physiol. 1961;200:1157-1163.

24. Malo J, Goldberg H, Graham R, et al. Effect of hypoxic hypoxia on systemic vasculature. J Appl Physiol. 1984;1403-1410.

25. Fermoso JD, Richardson QT, Guyton AC. Mechanism of decrease in cardiac output caused by opening the chest. Am J Physiol. 1964;207:1112.

26. Fessler HE, Brower RG, Wise RA, Permutt S. Effects of positive end-expiratory pressure on the gradient for venous return. Am Rev Respir Dis. 1991;19:143.

27. Pare PD, Warriner E, Baile M, Hogg JC. Redistribution of pulmo-nary extravascular lung water with positive end-expiratory pres-sure in canine pulmonary edema. Am Rev Respir Dis. 1983;127:590.

Section03-O-ref.indd 1 1/20/2015 7:10:20 AM

References2

28. Malo J, Ali J, Wood LDH. How does positive end-expiratory pressure reduce intrapulmonary shunt in canine pulmonary edema? J Appl Physiol. 1984;57:1002.

29. Pinsky M, Vincent J-L, Desmet J-M. Estimating left ventricu-lar filling pressure during positive end-expiratory pressure in humans. Am Rev Respir Dis. 1991;143:25.

30. Hall JB, Wood LDH. Acute hypoxemic respiratory failure. Med Grand Rounds. 1984;3:183.

31. Wood LDH, Hall JB. A mechanistic approach to providing adequate oxygenation in acute hypoxemic respiratory failure. Respir Care. 1993;38:784.

32. Siegal JH, Cerra FB, Coleman B, et al. Physiological and meta-bolic correlations in human sepsis. Surgery. 1979;186:163.

33. Vary TC. Increased pyruvate dehydrogenase kinase activity in response to sepsis. Am J Physiol. 1991;260:E669.

34. Curtis SE, Cain SM. Regional and systemic oxygen deliver/uptake relations and lactate flux in hyperdynamic, endotoxin treated dogs. Am Rev Respir Dis. 1992;145:348.

35. Hayes MA, Timmins AC, Yau EHS, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717.

36. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med. 1995;333:1025.

37. Humphrey H, Hall J, Sznajder F, et al. Improved survival in ARDS patients associated with a reduction in pulmonary capil-lary wedge pressure. Chest. 1990;97:1176.

38. Schuller D, Mitchell JP, Calandrino FS, Schuster DP. Fluid bal-ance during pulmonary edema: is fluid gain a marker or a cause of poor outcome? Chest. 1991;100:1068.

39. Mitchell JP, Schuller D, Calandrino FS, Schuster DP. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis. 1992;145:990.

40. The National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid management strategies in acute lung injury. N Engl J Med. 2006;354:2564-2575.

41. Manthous CA, Schumacker PT, Pohlman A, et al. Absence of supply dependence of oxygen consumption in patients with septic shock. J Crit Care. 1993;8:203.

42. Ronco JJ, Fenwick JC, Wiggs JR, et al. Oxygen consumption is independent of increases in oxygen delivery by dobutamine in septic patients who have normal or increased plasma lactate. Am Rev Respir Dis. 1993;147:25.

43. Martin C, Viviand X, Arnaud S, Vialet R, Rougnon T. Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med. 1999;27(9):1708-1713.

44. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483.

45. Granton JT, Goddard CM, Allard MF, et al. Leukocytes and decreased left ventricular contractility during endotoxemia in rabbits. Am J Respir Crit Care Med. 1997;155:1977.

46. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA. 1994;272:1354.

47. Meir-Hellman A, Reinahrt K, Bredle D, et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med. 1997;25:399.

48. Nevière R, Chagnon J-L, Vallet B. Dobutamine improves gastro-intestinal mucosal blood flow in a porcine model of endotoxic shock. Crit Care Med. 1997;25:1371.

49. De Backer D, Biston P, Devriendt J. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.

50. Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepinephrine dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med. 2011;39(3):450-455.

51. Manthous CA, Hall JB, Kushner R, et al. The effect of mechani-cal ventilation on oxygen consumption in critically ill patients. Am J Respir Crit Care Med. 1995;151:210.

52. Manthous CA, Hall JB, Olson D, et al. Effect of cooling on oxygen consumption in febrile critically ill patients. Am J Respir Crit Care Med. 1995;151:10.

53. Levin TN. Acute congestive heart failure: the need for aggressive therapy. Postgrad Med. 1997;101:97.

54. Scharf SM, Bianco JA, Tow DD, et al. The effects of large negative intrathoracic pressure on left ventricular function in patients with coronary artery disease. Circulation. 1981;63:871.

55. Bicknell WH, Wall MJ, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med. 1994;331:1105.

56. Salem R, Vallee F, Rusca M, Mebazaa A. Hemodynamic moni-toring by echocardiography in the ICU: the role of the new echo techniques. Curr Opin Crit Care. 2008;14(5):561-568.

57. Brown J, MacKinnon D, King A, et al. Elevated arterial blood pressure in cardiac tamponade. N Engl J Med. 1992;327:463.

58. Naunheim KS, Wood LDH, Little AG. Pulmonary edema: a com-plication of pericardial drainage. Surg Gyn Obst. 1987;165:166.

59. Ducas J, Prewitt RM. Pathophysiology and therapy of right ven-tricular dysfunction due to pulmonary embolism. Cardiovasc Clin. 1987;17:191.

60. Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest. 1997;111:218.

61. Lorell B, Leinbach RC, Pohost GM. Right ventricular infarction: clinical diagnosis and differentiation from cardiac tamponade and pericardial construction. Am J Cardiol. 1979;43:465.

62. Dell’Italia LJ, Starling MR, Blumhardt R, et al. Comparative effects of volume loading, dobutamine and nitroprusside in patients with predominant right ventricular infarction. Circulation. 1985;72:1327.

63. Bull TM, Clark B, McFann K, et al. Pulmonary vascular dys-function is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med. 2010;182,1123-1128.

64. Beiderlinden M, Kuehl H, Boes T, Peters J. Prevalence of pul-monary hypertension associated with severe acute respiratory distress syndrome: predictive value of computed tomography. Intensive Care Med. 2006;32:852-857.

65. Moloney ED, Evans TW. Pathophysiology and pharmacologi-cal treatment of pulmonary hypertension in acute respiratory distress syndrome. Euro Respr J. 2003;21:720-727.

66. Sandoval J, Long GR, Skoog C, Wood LD, Oppenheimer L. Independent influence of blood flow rate and mixed venous PO2 on shunt fraction. J Appl Physiol. 1983;55:1128-1133.


References 3

67. Rossant R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-406.

68. Delliger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syn-drome. Crit Care Med. 1999;25:911-999.

69. Gerlach H, Keh D, Semmerow A, et al. Dose-response charac-teristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 2003;67(7):1008-1015.

70. Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a ran-domized controlled trial. JAMA. 2004;291(13):1603-1609.

71. Teboul J-L, Besbes M, Andrivet P, et al. A bedside index assess-ing the reliability of pulmonary artery occlusion pressure measurements during mechanical ventilation with positive end-expiratory pressure. J Crit Care. 1992;7:22.

72. Connors AF, McCaffree DR, Gray BA. Evaluation of right heart catheterization in the critically ill patient without acute myocar-dial infarction. N Engl J Med. 1983;308:263.

73. Iberti TJ, Fischer EP, Leibowitz AB, et al. A multicentre study of physicians’ knowledge of the pulmonary artery catheter. JAMA. 1990;264:2928.

74. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgi-cal patients. N Engl J Med. 2003;348:5.

75. Richard C, Warszawski J, Anguel N, et al. Early use of the pul-monary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized con-trolled trial. JAMA. 2003;290:2713.

76. The National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Pulmonary-Artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 2006;354:2213-2224.

77. Connors AF, Dawson NV, Shaw PK, et al. Hemodynamic status in critically ill patients with and without acute heart disease. Chest. 1990;98:1200.

78. Steingrub JS, Celoria G, Vickers-Lahti M, et al. Therapeutic impact of pulmonary artery catheterization in a medical/ surgical ICU. Chest. 1991;99:1451.

79. Burger W, Jockwig B, Rucker G, Kober G. Influence of right ven-tricular pre- and afterload on right ventricular ejection fraction and preload recruitable stroke work relation. Clin Physiol. 2001;21(1):85-92.

80. von Euler U, Liljestrad G. Observations on the pulmonary arterial blood pressure of the cat. Acta Physiol Scand. 1946;12:301-320.

81. Waypa G, Schumacker PT. Oxygen sensing in hypoxic vasocon-striction, using new tools to answer an age old question. Exp Physiol. 2008;93:133-138.

82. Schumacker PT. Hypoxemia, anoxia and O2 sensing, the search continues. Am J Physio Lung Cell Mol Physiol. 2002;283:L918-L921.

83. Waypa G, Schumacker PT. Hypoxia-induced changes in pulmo-nary and systemic vascular resistance: where is the O2 sensor? Respir Physiol Neurobiol. 2010;174:201-211.

84. Taylor A, Parker J. Interstitial spaces and lymphatics. In: Fishman AP, Fisher AB, eds. Handbook of Physiology, Volume I, Section 3: The Respiratory System, Circulation and Nonrespiratory Function. Bethesda, MD: American Physiological Society; 1984:167.

85. Montaver JSG, Tsang J, Evans KG, et al. Alveolar epithelial damage: a critical difference between high pressure and oleic acid-induced low pressure edema. J Clin Invest. 1986;77:1786.

86. Matthay MA, Wiener-Kronish JP. Intact epithelial barrier func-tions is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis. 1990;142:1250.

87. Prewitt RM, McCarthy J, Wood LDH. Treatment of acute low pressure pulmonary edema in dogs: relative effects of hydro-static and oncotic pressure, nitroprusside and PEEP. J Clin Invest. 1981;67:409.

88. Wood LDH, Prewitt RM. Cardiovascular management in acute hypoxemic respiratory failure. Am J Cardiol. 1981;47:963.

89. Amato MBP, Barbas CSV, Medeiros DM, et al. Beneficial effects of the “open lung approach” with low distending pressures in acute respiratory distress syndrome: a prospective randomized study on mechanical ventilation. Am J Respir Crit Care Med. 1995;152:1835.

90. Brower RG, Lanken PN, Macintyre N, et al. Higher versus lower positive end-expiratory pressure in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327-336.

91. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-1308.

92. Long GR, Breen PH, Mayers I, Wood LDH. Treatment of canine aspiration pneumonitis: fluid volume reduction versus fluid volume expansion. J Appl Physiol. 1988;65:1736.

93. Sznajder JI, Zucker AR, Wood LDH, Long GR. Effect of plasma-pheresis and hemofiltration on acid aspiration pulmonary edema. Am Rev Respir Dis. 1986;134:222.


Chapter 32

REFERENCES

1. Pinsky MR. Hemodynamic evaluation and monitoring in the ICU. Chest. 2007;132:2020-2029. [overview of the rationale for hemodynamic monitoring]

2. Antonelli M, Levy M, Andrews PJ, et al. Hemodynamic moni-toring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive Care Med. 2007;33:575-590.

3. Vincent JL, Rhodes A, Perel A, et al. Update on hemodynamic monitoring: a consensus of 16. Crit Care. 2011;15:229 [posi-tion statement on all the devices discussed in this chapter from a diverse group of extremely well-published investigators]

4. LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of per-fusion pressure on tissue perfusion in septic shock. Crit Care Med. 2000;28:2729-2732. [rationale for targeting a mean arterial pressure of >60 mm Hg]

5. Broder G, Weil MH. Excess lactate: an index of reversibility of shock in human patients. Science. 1964;143:1457-1459.

6. Bakker J, Coffernils M, Leon M, Gris P, Vincent JL. Blood lactate levels are superior to oxygen-derived variables in predicting outcome in human septic shock. Chest. 1991;99:956-962.

7. Moller JT, Pedersen T, Rasmussen LS, et al. Randomized evalu-ation of pulse oximetry in 20,802 patients: I. Design, demog-raphy, pulse oximetry failure rate and overall complication rate. Anesthesiology. 1993;78:436-444. [largest study to examine pulse oximetry showing absolutely no clinical outcome benefit]

8. Wukitisch, MW, Peterson MT, Tobler DR, Pologe JA. Pulse oximetry: analysis of theory, technology, and practice. J Clin Monit. 1988;4:290-301.

9. Van de Louw A, Cracco C, Cerf C, et al. Accuracy of pulse oximetry in the intensive care unit. Intensive Care Med. 2001;27: 1606-1613.

10. Michard F, Chemla D, Richard C, et al. Clinical use of respiratory changes in arterial pulse pressure to monitor the hemodynamic effects of PEEP. Am J Respir Crit Care Med. 1999;159:935-939.

11. Michard F, Boussat S, Chemla D, et al. Relation between respira-tory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med. 2000;162:134-138. [first major clinical study docu-menting the usefulness of pulse pressure variation as a predictor of volume responsiveness]

12. Cassesson M, Besnard C, Durand PG, Bohe J, Jacques D. Relation between respiratory variations in pulse oximetry ple-thysmographic waveform amplitude and arterial pulse pressure

in ventilated patients. Crit Care. 2005;9:R562-R568. [first clinical study showing that the pulse oximeter plethysmographic density profiles could be used as a surrogate for arterial pulse pressure to assess volume responsiveness]

13. Natalini G, Rosano A, Taranto M, Faggian B, Vittorielli E, Bernardini A. Arterial versus plethysmographic dynamic indices to test responsiveness for testing fluid administra-tion in hypotensive patients: a clinical trial. Anesth Analg. 2006;103:1478-1484.

14. Schmidt-Nielsen K. Circulation. In: Animal Physiology, 4th ed. Cambridge UK: Cambridge University Press; 1983:97-133.

15. DeBacker D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002;166:98-104.

16. Scheinman MM, Brown MA, Rapaport E. Critical assessment of use of central venous oxygen saturation as a mirror of mixed venous oxygen in severely ill cardiac patients. Circulation. 1969;40:165-172.

17. Reinhart K, Rudolph T, Bredle DL, Hannemann L, Cain SM. Comparison of central-venous to mixed-venous oxygen sat-uration during changes in oxygen supply/demand. Chest. 1989;95:1216-1221.

18. Lee J, Wright F, Barber R, Stanley L. Central venous oxygen saturation in shock: a study in man. Anesthesiology. 1972;36: 472-478.

19. Mulier KE, Skarda DE, Taylor JH, et al. Near-infrared spectros-copy in patients with severe sepsis: correlation with invasive hemodynamic measurements. Surg Infect. 2008;9:515-519.

20. Ruokonen E, Takala J, Uusaro A. Effect of vasoactive treatment on the relationship between mixed venous and regional oxygen saturation. Crit Care Med. 1991;19:1365-1369.

21. Dueck MH, Klimek M, Appenrodt S, Weigand C, Boerner U. Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation dur-ing varying hemodynamic conditions. Anesthesiology. 2005;103:249-257.

22. Reinhart K, Kuhn HJ, Hartog C, Bredle DL. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med. 2004;30:1572-1578. [one of the larger original studies showing the similarities and differences in SvO2 and ScvO2 in humans]

23. Cohn SM, Crookes BA, Proctor KG. Near-infrared spectroscopy in resuscitation. J Trauma. 2003;54:S199-S202.


References2

24. Cohn SM, Nathens AB, Moore FA, et al. Tissue oxygen satura-tion predicts the development of organ dysfunction during traumatic shock resuscitation. J Trauma. 2007;62:44-54.

25. Payen D, Luengo C, Heyer L, et al. Is thenar tissue hemo-globin oxygen saturation in septic shock related to macro-hemodynamic variables and outcome? Critical Care. 2009; 13(suppl 5):S6.

26. Mesquida J, Masip J, Gili G, Artigas A, Baigorri F. Thenar oxygen saturation measured by near infrared spectroscopy as a noninvasive predictor of low central venous oxygen saturation in septic patients. Intensive Care Med. 2009;35:1106-1109.

27. Lima A, Bakker J. Noninvasive monitoring of peripheral perfu-sion. Intensive Care Med. 2005;31:1316-1326.

28. Gomez H, Torres A, Polanco P, et al. Use of non-invasive NIRS during a vascular occlusion test to assess dynamic tissue O2 saturation response. Intensive Care Med. 2008;34:1600-1607. [first clinical study to examine the determinants of StO2 change during the vascular occlusion test]

29. Pinsky MR. Functional hemodynamic monitoring. Intensive Care Med. 2002;28:386-388.

30. Gomez H, Mesquida J, Simon P, et al. Characterization of StO2 and VOT: influence of measurement sites, probe sizes and defla-tion thresholds. Crit Care. 2009;13(suppl 5):S3. doi:10.1186/cc8001.

31. Lorsomradee S, Lorsomradee SR, Cromheecke S, De Hert SG. Continuous cardiac output measurement: arterial pressure anal-ysis versus thermodilution technique during cardiac surgery with cardiopulmonary bypass. Anaesthesia. 2007;62:979-983.

32. Shure D. Pulmonary-artery catheters-peace at last? N Engl J Med. 2006;354:2273-2274.

33. Pinsky MR. Determinants of pulmonary artery flow variation during respiration. Appl Physiol. 1984;56:1237-1245.

34. Mihm FG, Gettinger A, Hanson CW III, et al. A multicenter evaluation of a new continuous cardiac output pulmonary artery catheter system. Crit Care Med. 1998;26:1346-1350.

35. Swan HJ, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med. 1970;283: 447-451.

36. Pinsky MR. Clinical significance of pulmonary artery occlusion pressure. Intensive Care Med. 2003;29:175-178.

37. Pinsky MR, Vincent JL. Let us use the pulmonary artery catheter correctly and only when we need it. Crit Care Med. 2005;33:1119-1122.

38. Vincent JL, Pinsky MR, Sprung CL, et al. The pulmonary artery catheter: in medio virtus. Crit Care Med. 2008;36:3093-3096.

39. Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pul-monary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA. 2005;294:1664-1670. [system-atic review of many of the clinical studies showing no effect of pul-monary artery catheterization on outcome from critical illness]

40. Sakka SG, Reinhart K, Meier-Hellmann A. Comparison of pulmonary artery and arterial thermodilution cardiac output in critically ill patients. Intensive Care Med. 1999;25:843-846.

41. Costa MG, Della RG, Chiarandini P, et al. Continuous and intermittent cardiac output measurement in hyperdynamic conditions: pulmonary artery catheter vs lithium dilution tech-nique. Intensive Care Med. 2008;34:257-263.

42. Langewouters GJ, Wesseling KH, Goedhard WJA. The static elastic properties of 45 human thoracic and 20 abdominal aortas in vitro and the parameters of a new model. J Biomech. 1984;17:425-435.

43. Hamilton WF, Remington JW. The measurement of stroke volume from the pulse pressure. Am J Physiol. 1947;148:14-24. [the original study on use of pressure pulse to assess flow in a canine model]

44. Opdam HI, Wan L, Bellomo R. A pilot assessment of the FloTrac cardiac output monitoring system. Intensive Care Med. 2007;33:344-349.

45. Della Rocca G, Costa MG, Pompei L, Coccia C, Pietropaoli P. Continuous and intermittent cardiac output measurement: pulmonary artery catheter versus aortic transpulmonary tech-nique. Br J Anaesth. 2002;88:350-356.

46. Jonas MM, Kelly FE, Linton RA, Band DM, O'Brien TK, Linton NW. A comparison of lithium dilution cardiac output measure-ments made using central and antecubital venous injection of lithium chloride. J Clin Monit Comput. 1999;15:525-528.

47. McGee WT, Horswell JL, Calderon J, et al. Validation of a con-tinuous, arterial pressure-based cardiac output measurement: a multicenter, prospective clinical trial. Crit Care. 2007;11:R105.

48. Hadian M, Kim H, Severyn DA, Pinsky MR. Cross-comparison of cardiac output trending accuracy of LiDCO, PiCCO, FloTrac and pulmonary artery catheters. Crit Care. 2010;14:R212. [clini-cal study comparing most commercially available cardiac output monitoring devices to each other]

49. Gunn S, Kim HK, Harrigan P, Pinsky MR. Ability of aortic pulse contour and esophageal pulsed Doppler measures to estimate changes in left ventricular output. Intensive Care Med. 2006;32(10):1537-1546.

50. Hatib F, Jansen JRC, Pinsky MR. Peripheral vascular decoupling in porcine endotoxic shock. J Appl Physiol. 2011;111(3):853-860. doi: 10.1152/japplphysiol.00066.2011. [physiological study dem-onstrating why changes in peripheral vasomotor may markedly impair existing cardiac output algorithms ability to estimate cardiac output because peripheral vascular compliance changes can be great]

51. Pinsky MR, Payen D. Functional hemodynamic monitoring. Crit Care. 2005;9:566-572.

52. Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients. Chest. 2002;121:2000-2008. [meta-analysis demonstrat-ing the uselessness of traditional static hemodynamic measures to predict volume responsiveness]

53. Berkenstadt H, Margalit N, Hadani M, et al. Stroke volume variation as a predictor of fluid responsiveness in patients undergoing brain surgery. Anesth Analg. 2001;92:984-989.

54. Reuter D, Felbinger TW, Schmidt C, et al. Stroke volume varia-tion for assessment of cardiac responsiveness to volume load-ing in mechanically ventilated patients after cardiac surgery. Intensive Care Med. 2002;28:392-398.

55. Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest. 2002;121: 2000-2008.

56. Monnet X, Rienzo M, Osman D, et al. Response to leg raising predicts fluid responsiveness during spontaneous breathing or with arrhythmia. Crit Care Med. 2006;34:1402-1407.

57. Schmidt GA, Koenig S, Mayo PH. Shock: ultrasound to guide diagnosis and therapy. Chest. 2012;142:1042-1048.


References 3

58. Lopes MR, Oliveira MA, Pereira VO, Lemos IP, Auler JO Jr, Michard F. Goal-directed fluid management based on pulse pressure variation monitoring during high-risk surgery: a pilot randomized controlled trial. Crit Care. 2007;11:R100. [clinical trial using pulse pressure variation minimization to improve out-come in high-risk surgical patients]

59. Boyd O, Grounds M, Bennett ED. A randomized clinical trial of the effect of deliberate preoperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA. 1993;270:2699-2707.

60. Sinclair S, James S, Singer M. Intraoperative intravascular volume optimisation and length of hospital stay after repair of proximal femoral fracture: randomised controlled trial. BMJ. 1997;315:909-912.

61. Lobo S, Salgado P, Castillo VGT, et al. Effects of maximizing oxygen delivery on morbidity and mortality in high-risk surgi-cal patients. Crit Care Med. 2000;28:3396-3404.

62. Gan TJ, Soppitt A, Maroof M, et al. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology. 2002;97:820-826.

63. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, con-trolled trial [ISRCTN38797445]. Crit Care. 2005;9:R687-R693. [functional application of hemodynamic monitoring to guide resuscitation therapy in postoperative critically ill patients]

64. Rhodes A, Cecconi M, Hamilton M, et al. Goal-directed ther-apy in high-risk surgical patients: a 15-year follow-up study. Intensive Care Med. 2010:36:1327-1332. [long-term follow-up documenting improved patient-centered outcomes for goal-directed therapy]


Chapter 33

REFERENCES

1. Cohn JN. Blood pressure measurement in shock. Mechanism of inaccuracy in ausculatory and palpatory methods. JAMA. 1967;199(13):118-122.

2. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327.

3. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.

4. Menon V, Hochman JS. Management of cardiogenic shock complicating acute myocardial infarction. Heart. 2002;88(5): 531-537.

5. Grassino A, Macklem PT. Respiratory muscle fatigue and venti-latory failure. Annu Rev Med. 1984;35:625-647.

6. Hussain SN, Roussos C. Distribution of respiratory muscle and organ blood flow during endotoxic shock in dogs. J Appl Physiol. 1985;59(6):1802-1808.

7. Del Sorbo L, Slutsky AS. Ventilatory support for acute respi-ratory failure: new and ongoing pathophysiological, diag-nostic and therapeutic developments. Curr Opin Crit Care. 2010;16(1):1-7.

8. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308.

9. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117(5):686-697.

10. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA. Lactate clearance vs central venous oxygen satura-tion as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303(8):739-746.

11. de Guzman E, Shankar MN, Mattox KL. Limited volume resus-citation in penetrating thoracoabdominal trauma. AACN Clin Issues. 1999;10(1):61-68.

12. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, ran-domized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409-417.

13. Bickell WH, Wall MJ Jr, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with pen-etrating torso injuries. N Engl J Med. 1994;331(17):1105-1109.

14. Ruokonen E, Parviainen I, Uusaro A. Treatment of impaired perfusion in septic shock. Ann Med. 2002;34(7-8):590-597.

15. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007;370(9588):676-684.

16. De Backer D, Biston P, Devriendt J, et al. Comparison of dopa-mine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.

17. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34(12):2226-2234.

18. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepi-nephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-887.

19. Gordon AC, Russell JA, Walley KR, et al. The effects of vaso-pressin on acute kidney injury in septic shock. Intensive Care Med. 2010;36(1):83-91.

20. Walley KR. Use of central venous oxygen saturation to guide therapy. Am J Respir Crit Care Med. 2010;184(5):514-520.

21. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.

22. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mor-tality in patients with septic shock. JAMA. 2002;288(7):862-871.

23. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a ran-domised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.

24. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596.

25. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.

26. Michard F, Boussat S, Chemla D, et al. Relation between respira-tory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med. 2000;162(1):134-138.

27. Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically


References2

ill patients. SUPPORT Investigators. JAMA. 1996;276(11): 889-897.

28. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgi-cal patients. N Engl J Med. 2003;348(1):5-14.

29. Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breath-ing spontaneously. N Engl J Med. 1996;335(25):1864-1869.

30. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interrup-tion of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471-1477.

31. McGee S, Abernethy WB III, Simel DL. The rational clini-cal examination. Is this patient hypovolemic? JAMA. 1999;281(11):1022-1029.

32. Rush BF Jr. Irreversibility in the post-transfusion phase of hem-orrhagic shock. Adv Exp Med Biol. 1971;23(0):215-234.

33. Reilly PM, Wilkins KB, Fuh KC, Haglund U, Bulkley GB. The mesenteric hemodynamic response to circulatory shock: an overview. Shock. 2001;15(5):329-343.

34. Walley KR, Cooper DJ. Diastolic stiffness impairs left ventricu-lar function during hypovolemic shock in pigs. Am J Physiol. 1991;260(3 Pt 2):H702-H712.

35. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247-2256.

36. Rame JE, Dries DL, Drazner MH. The prognostic value of the physical examination in patients with chronic heart failure. Congest Heart Fail. 2003;9(3):170-175, 178.

37. Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med. 1976;295(25):1404-1413.

38. Page DL, Caulfield JB, Kastor JA, DeSanctis RW, Sanders CA. Myocardial changes associated with cardiogenic shock. N Engl J Med. 1971;285(3):133-137.

39. Pfisterer M. Right ventricular involvement in myocardial infarc-tion and cardiogenic shock. Lancet. 2003;362(9381):392-394.

40. Daneshvar D, Wei J, Tolstrup K, Thomson LE, Shufelt C, Merz CN. Diastolic dysfunction: improved understanding using emerging imaging techniques. Am Heart J. 2010;160(3): 394-404.

41. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treat-ment. Circulation. 2002;105(12):1503-1508.

42. Lipkin DP, Frenneaux M, Maseri A. Beneficial effect of captopril in cardiogenic shock. Lancet. 1987;2(8554):327.

43. Hurst JW. Right ventricular infarction. N Engl J Med. 1994;331(10):681.

44. Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK regis-try. J Am Coll Cardiol. 2003;41(8):1273-1279.

45. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143-1150.

46. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100(4):483-490.

47. Walley KR. Many roles of nitric oxide in regulating cardiac function in sepsis. Crit Care Med. 2000;28(6):2135-2137.

48. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagno-sis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477-480. e1-42.

49. Cooper DS. Hyperthyroidism. Lancet. 2003;362(9382):459-468. 50. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical

review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;92(4):1217-1225.

51. Hochman JS. Cardiogenic shock complicating acute myo-cardial infarction: expanding the paradigm. Circulation. 2003;107(24):2998-3002.

52. Walley KR. Heterogeneity of oxygen delivery impairs oxy-gen extraction by peripheral tissues: theory. J Appl Physiol. 1996;81(2):885-894.

53. Favory R, Neviere R. Significance and interpretation of elevated troponin in septic patients. Crit Care. 2006;10(4):224.

54. Cooper DJ, Herbertson MJ, Werner HA, Walley KR. Bicarbonate does not increase left ventricular contractility during L-lactic acidemia in pigs. Am Rev Respir Dis. 1993;148(2):317-322.


Chapter 34

REFERENCES

1. Swaroop M, Straus DC, Agubuzu O, Esposito TJ, Schermer CR, Crandall ML. Pre-hospital transport times and survival for hypotensive patients with penetrating thoracic trauma. J Emerg Trauma Shock. 2013;6:16-20.

2. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.

3. Hayes MA, Timmins AC, Yau EH, et al. Oxygen transport pat-terns in patients with sepsis syndrome or septic shock: influ-ence of treatment and relationship to outcome. Crit Care Med. 1997;25:926-936.

4. Adrie C, Adib-Conquy M, Laurent I, et al. Successful cardio-pulmonary resuscitation after cardiac arrest as a sepsis-like syndrome. Circulation. 2002;106:562-568.

5. Durairaj L, Schmidt GA. Fluid therapy in resuscitated sepsis: less is more. Chest. 2008;133:252-263.

6. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564-2575.

7. Yu M, Levy MM, Smith P, et al. Effect of maximizing oxy-gen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. Crit Care Med. 1993;21:830-838.

8. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717-1722.

9. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal- oriented hemo-dynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med. 1995;333:1025-1032.

10. Schmidt GA. Counterpoint: adherence to early goal-directed therapy. Does it really matter? No. Both risks and benefits require further study. Chest. 2010;138:480-484.

11. Malbrain ML, Chiumello D, Pelosi P, et al. Incidence and prog-nosis of intraabdominal hypertension in a mixed population of critically ill patients: a multiple-center epidemiological study. Crit Care Med. 2005;33:315-322.

12. McNelis J, Marini CP, Jurkiewicz A, et al. Predictive fac-tors associated with the development of abdominal compart-ment syndrome in the surgical intensive care unit. Arch Surg. 2002;137:133-136.

13. Humphrey H, Hall J, Sznajder I, et al. Improved survival in ARDS patients associated with a reduction in pulmonary capil-lary wedge pressure. Chest. 1990;97:1176-1180.

14. Simmons RS, Berdine GG, Seidenfeld JJ, et al. Fluid balance and the adult respiratory distress syndrome. Am Rev Respir Dis. 1987;135:924-929.

15. Alsous F, Khamiees M, DeGirolamo A, et al. Negative fluid bal-ance predicts survival in patients with septic shock: a retrospec-tive pilot study. Chest. 2000;117:1749-1754.

16. Vincent J-L, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344-353.

17. Boyd JH, Forbes J, Nakada T, Walley KR, Russell JA. Fluid resus-citation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011;39:259-265.

18. Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422-427.

19. Uchino S, Bellomo R, Morimatsu H, et al. Pulmonary artery catheter versus pulse contour analysis: a prospective epidemio-logical study. Crit. Care. 2006;10:R174.

20. Challand C, Struthers R, Sneyd JR, et al. Randomized controlled trial of intraoperative goal-directed fluid therapy in aerobi-cally fit and unfit patients having major colorectal surgery. Br J Anaesth. 2012;108:53-62.

21. Upadya A, Tilluckdharry L, Muralidharan V, et al. Fluid balance and weaning outcomes. Intensive Care Med. 2005;31:1643-1647.

22. Epstein CD, Peerless JR. Weaning readiness and fluid balance in older critically ill surgical patients. Am J Crit Care. 2006;15:54-64.

23. Corcoran T, Rhodes JE, Clarke S, Myles PS, Ho KM. Perioperative fluid management strategies in major surgery: a stratified meta-analysis. Anesth Analg. 2012;114:640-651.

24. Mitchell JP, Schuller D, Calandrino FS, et al. Improved outcome based on fluid management in critically ill patients requir-ing pulmonary artery catheterization. Am Rev Respir Dis. 1992;145:990-998.

25. Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. New Engl J Med. 2011;364:2483-2495.

26. Magder S, Bafaqeeh F. The clinical role of central venous pres-sure measurements. J Intensive Care Med. 2007;22:44-51.

27. Marik PE, Baram M, Vahid B. Does central venous pressure pre-dict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008;134:172-178.


References2

28. Osman D, Ridel C, Ray P, et al. Cardiac filling pressures are not appropriate to predict hemodynamic response to volume chal-lenge. Crit Care Med. 2007;35:64-68.

29. Michard F, Boussat S, Chemla D, et al. Relation between respira-tory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med. 2000;162:134-138.

30. Tavernier B, Makhotine O, Lebuffe G, et al. Systolic pressure variation as a guide to fluid therapy in patients with sepsis-induced hypotension. Anesthesiology. 1998;89:1313-1321.

31. Feissel M, Michard F, Mangin I, Ruyer O, Faller JP, Teboul JL. Respiratory changes in aortic blood velocity as an indicator of fluid responsiveness in ventilated patients with septic shock. Chest. 2001;119:867-873.

32. Sakka SG, Bredle DL, Reinhart K, et al. Comparison between intrathoracic blood volume and cardiac filling pressures in the early phase of hemodynamic instability of patients with sepsis or septic shock. J Crit Care. 1999;14:78-83.

33. Michard F, Alaya S, Zarka V, et al. Global end-diastolic volume as an indicator of cardiac preload in patients with septic shock. Chest. 2003;124:1900-1908.

34. Feissel M, Michard F, Faller JP, et al. The respiratory variation in inferior vena cava diameter as a guide to fluid therapy. Intensive Care Med. 2004;30:1834-1837.

35. Feissel M, Teboul JL, Merlani P, et al. Plethysmographic dynamic indices predict fluid responsiveness in septic ventilated patients. Intensive Care Med. 2007;33:993-999.

36. Vieillard-Baron A, Chergui K, Rabiller A, et al. Superior vena caval collapsibility as a gauge of volume status in ventilated septic patients. Intensive Care Med. 2004;30:1734-1739.

37. Barbier C, Loubieres Y, Schmit C, et al. Respiratory changes in inferior vena cava diameter are helpful in predicting fluid responsiveness in ventilated septic patients. Intensive Care Med. 2004;30:1740-1746.

38. Perner A, Faber T. Stroke volume variation does not predict fluid responsiveness in patients with septic shock on pres-sure support ventilation. Acta Anaesthesiol Scand. 2006;50: 1068-1073.

39. Kumar A, Anel R, Bunnell E, et al. Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volume, cardiac performance, or the response to volume infusion in normal subjects. Crit Care Med. 2004;32:691-699.

40. Reuse C, Vincent JL, Pinsky MR. Measurements of right ventricu-lar volumes during fluid challenge. Chest. 1990;98:1450-1454.

41. Wagner JG, Leatherman JW. Right ventricular end-diastolic volume as a predictor of the hemodynamic response to a fluid challenge. Chest. 1998;113:1048-1054.

42. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873.

43. Raper R, Sibbald WJ. Misled by the wedge? The Swan-Ganz catheter and left ventricular preload. Chest. 1986;89:427-434.

44. Tavernier B, Makhotine O, Lebuffe G, et al. Systolic pressure variation as a guide to fluid therapy in patients with sepsis-induced hypotension. Anesthesiology. 1998;89:1313-1321.

45. Lamia B, Ochagavia A, Monnet X, Chemla D, Richard C, Teboul JL. Echocardiographic prediction of volume responsiveness in critically ill patients with spontaneously breathing activity. Intensive Care Med. 2007;33:1125-1132.

46. Solus-Biguenet H, Fleyfel M, Tavernier B, et al. Non-invasive prediction of fluid responsiveness during major hepatic surgery. Br J Anaesth. 2006;97:808-816.

47. Monnet X, Rienzo M, Osman D, et al. Esophageal Doppler monitoring predicts fluid responsiveness in critically ill venti-lated patients. Intensive Care Med. 2005;31:1195-1201.

48. Monnet X, Rienzo M, Osman D, et al. Passive leg raising pre-dicts fluid responsiveness in the critically ill. Crit Care Med. 2006;34:1402-1407.

49. Michard F, Alaya S, Zarka V, et al. Global end-diastolic volume as an indicator of cardiac preload in patients with septic shock. Chest. 2003;124:1900-1908.

50. Biais M, Vidil L, Sarrabay P, Cottenceau V, Revel P, Sztark F. Changes in stroke volume induced by passive leg rais-ing in spontaneously breathing patients: comparison between echocardiography and Vigileo™/FloTrac™ device. Crit Care. 2009;13:R195.

51. Cavallaro F, Sandroni C, Marano C, et al. Diagnostic accuracy of passive leg raising for prediction of fluid responsiveness in adults: systematic review and meta-analysis of clinical studies. Intensive Care Med. 2010;36:1475-1483.

52. Maizel J, Airapetian N, Lorne E, et al. Diagnosis of central hypovolemia by using passive leg raising. Intensive Care Med. 2007;33:1133-1138.

53. Lafanechere A, Pene F, Goulenok C, et al. Changes in aortic blood flow induced by passive leg raising predict fluid respon-siveness in critically ill patients. Crit Care. 2006;10:R132.

54. Brun C, Zieleskiewicz L, Textoris J, et al. Prediction of fluid responsiveness in severe preeclamptic patients with oliguria. Intensive Care Med. 2013;39:593-600.

55. Préau S, Saulnier F, Dewavrin F, Durocher A, Chagnon J-L. Passive leg raising is predictive of fluid responsiveness in spontaneously breathing patients with severe sepsis or acute pancreatitis. Crit Care Med. 2010;38:819-825.

56. Thiel SW, Kollef MH, Isakow W. Non-invasive stroke volume measurement and passive leg raising predict volume respon-siveness in medical ICU patients: an observational cohort study. Crit Care. 2009;13:R111.

57. Mahjoub Y, Touzeau J, Airapetian N, et al. The passive leg-raising maneuver cannot accurately predict fluid responsiveness in patients with intra-abdominal hypertension. Crit Care Med. 2010;38:1824-1829.

58. Mahjoub Y, Pila C, Friggeri A, et al. Assessing fluid responsive-ness in critically ill patients: false-positive pulse pressure varia-tion is detected by Doppler echocardiographic evaluation of the right ventricle. Crit Care Med. 2009;37:2570-2575.

59. Monnet X, Bleibtreu A, Dres M, Gharbi R, Richard C, Teboul JL. Passive leg-raising and end-expiratory occlusion tests perform better than pulse pressure variation in patients with low respira-tory system compliance. Crit Care Med. 2012;40:152-1557.

60. Biais M, Nouette-Gaulain K, Roullet S, Quinart A, Revel P, Sztark F. A comparison of stroke volume variation measured by Vigileo™/FloTrac™ system and aortic Doppler echocardiography. Anesth Analg. 2009;109:466-469.

61. Perel A, Pizov R, Cotev S. Systolic blood pressure variation is a sensitive indicator of hypovolemia in ventilated dogs subjected to graded hemorrhage. Anesthesiology. 1987;67:498-502.

62. Preisman S, Kogan S, Berkenstadt H, et al. Predicting fluid responsiveness in patients undergoing cardiac surgery: func-tional haemodynamic parameters including the Respiratory


References 3

Systolic Variation Test and static preload indicators. Br J Anaesth. 2005;95:746-755.

63. De Backer D, Heenen S, Piagnerelli M, et al. Pulse pressure variations to predict fluid responsiveness: influence of tidal volume. Intensive Care Med. 2005;31:517-523.

64. Kramer A, Zygun D, Hawes H, et al. Pulse pressure variation predicts fluid responsiveness following coronary artery bypass surgery. Chest. 2004;126:1563-1568.

65. Monnet X, Chemla D, Osman D, et al. Measuring aortic diam-eter improves accuracy of esophageal Doppler in assessing fluid responsiveness. Crit Care Med. 2007;35:477-482.

66. Brennan JM, Blair JE, Hampole C, et al. Radial artery pulse pressure variation correlates with brachial artery peak veloc-ity variation in ventilated subjects when measured by internal medicine residents using hand-carried ultrasound devices. Chest. 2007;131:1301-1307.

67. Monge García MI, Gil Cano A, Díaz Monrové JC. Brachial artery peak velocity variation to predict fluid responsiveness in mechanically ventilated patients. Crit Care. 2009;13:R142.

68. Vieillard-Baron A, Chergui K, Rabiller A, et al. Superior vena caval collapsibility as a gauge of volume status in ventilated septic patients. Intensive Care Med. 2004;30:1734-1739.

69. Magder S, Georgiadis G, Cheong T. Respiratory variations in right atrial pressure predict the response to fluid challenge. J Crit Care. 1992;7:76-85.

70. Heenen S, De Backer D, Vincent JL. How can the response to volume expansion in patients with spontaneous respiratory movements be predicted? Crit Care. 2006;10:R102.

71. Bouferrache K, Amiel J-B, Chimot L, et al. Initial resuscitation guided by the Surviving Sepsis Campaign recommendations and early echocardiographic assessment of hemodynamics in intensive care unit septic patients: a pilot study. Crit Care Med. 2012;40:2821-2827.


Chapter 35

REFERENCES

1. Elzinga G, Westerhof N. How to quantify pump function of the heart. The value of variables derived from measurements on isolated muscle. Circ Res. 1979;44(3):303-308.

2. Joshi N. The third heart sound. South Med J. 1999;92(8): 756-761.

3. Labovitz AJ, Noble VE, Bierig M, et al. Focused cardiac ultrasound in the emergent setting: a consensus statement of the American Society of Echocardiography and American College of Emergency Physicians. J Am Soc Echocardiogr. 2010;23(12):1225-1230.

4. Salem R, Vallee F, Rusca M, Mebazaa A. Hemodynamic moni-toring by echocardiography in the ICU: the role of the new echo techniques. Curr Opin Crit Care. 2008;14(5):561-568.

5. Burger W, Jockwig B, Rucker G, Kober G. Influence of right ventricular pre- and afterload on right ventricular ejection frac-tion and preload recruitable stroke work relation. Clin Physiol. 2001;21(1):85-92.

6. Kass DA, Maughan WL, Guo ZM, Kono A, Sunagawa K, Sagawa K. Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation. 1987;76(6):1422-1436.

7. Cooper DJ, Thompson CR, Walley KR, Gillis RP, Wolinski-Walley PE, Schellenberg RR. Histamine decreases left ven-tricular contractility in normal human subjects. J Appl Physiol. 1992;73(6):2530-2537.

8. Andrew P. Diastolic heart failure demystified. Chest. 2003;124(2):744-753.

9. Kaplan A, Mayo PH. Echocardiography performed by the pul-monary/critical care medicine physician. Chest. 2009;135(2): 529-535.

10. Vieillard-Baron A, Slama M, Cholley B, Janvier G, Vignon P. Echocardiography in the intensive care unit: from evolution to revolution? Intensive Care Med. 2008;34(2):243-249.

11. Vincent J-L, Rhodes A, Perel A, et al. Update on hemodynamic monitoring: a consensus of 16. Critical Care. 2011;15:229.

12. Walley KR. Use of central venous oxygen saturation to guide therapy. Am J Respir Crit Care Med. 2011;184:514.

13. Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA. 1996;276(11):889-897.

14. Sandham JD, Hull RD, Brant RF, et al. Randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgi-cal patients. N Engl J Med. 2003;348(1):5-14.

15. Chittock DR, Dhingra VK, Ronco JJ, et al. Severity of illness and risk of death associated with pulmonary artery catheter use. Crit Care Med. 2004;32(4):911-915.

16. Sarnoff SJ, Berglund E. Ventricular function. I. Starling’s law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation. 1954;9(5): 706-718.

17. Sagawa K. The ventricular pressure-volume diagram revisited. Circ Res. 1978;43(5):677-687.

18. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348(18):1756-1763.

19. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res. 2000;45(4):813-825.

20. Cowley AW Jr, Guyton AC. Heart rate as a determinant of cardiac output in dogs with arteriovenous fistula. Am J Cardiol. 1971;28(3):321-325.

21. Jacobsohn E, Chorn R, O'Connor M. The role of the vasculature in regulating venous return and cardiac output: historical and graphical approach. Can J Anaesth. 1997;44(8):849-867.

22. Goldberg HS, Rabson J. Control of cardiac output by systemic vessels. Circulatory adjustments to acute and chronic respira-tory failure and the effect of therapeutic interventions. Am J Cardiol. 1981;47(3):696-702.

23. Henderson WR, Griesdale DE, Walley KR, Sheel AW. Clinical review: Guyton–the role of mean circulatory filling pressure and right atrial pressure in controlling cardiac output. Crit Care. 2010;14(6):243.

24. Luk A, Ahn E, Soor GS, Butany J. Dilated cardiomyopathy: a review. J Clin Pathol. 2009;62(3):219-225.

25. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling— concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569-582.

26. Shaw T, Elliott P, McKenna WJ. Dilated cardiomyopathy: a genetically heterogeneous disease. Lancet. 2002;360(9334): 654-655.


References2

27. Wu AH, Cody RJ. Medical and surgical treatment of chronic heart failure. Curr Probl Cardiol. 2003;28(3):229-260.

28. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 1995;91(10):2504-2507.

29. Suga H, Yamada O, Goto Y. Energetics of ventricular con-traction as traced in the pressure-volume diagram. Fed Proc. 1984;43(9):2411-2413.

30. Weinberg G. Lipid rescue resuscitation from local anaesthetic cardiac toxicity. Toxicol Rev. 2006;25(3):139-145.

31. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunc-tion via the receptor for advanced glycation end products. Circ Res. 2008;102(10):1239-1246.

32. Herbertson MJ, Werner HA, Russell JA, Iversen K, Walley KR. Myocardial oxygen extraction ratio is decreased during endo-toxemia in pigs. J Appl Physiol. 1995;79(2):479-486.

33. Lorigados CB, Soriano FG, Szabo C. Pathomechanisms of myo-cardial dysfunction in sepsis. Endocr Metab Immune Disord Drug Targets. 2010;10(3):274-284.

34. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation. 1987;75(3):533-541.

35. Walley KR, Becker CJ, Hogan RA, Teplinsky K, Wood LD. Progressive hypoxemia limits left ventricular oxygen consump-tion and contractility. Circ Res. 1988;63(5):849-859.

36. Endoh M. Acidic pH-induced contractile dysfunction via downstream mechanism: identification of pH-sensitive domain in troponin I.[comment]. J Mol Cell Cardiol. 2001;33(7): 1297-1300.

37. Walley KR, Lewis TH, Wood LD. Acute respiratory acidosis decreases left ventricular contractility but increases cardiac output in dogs. Circ Res. 1990;67(3):628-635.

38. Teplinsky K, O’Toole M, Olman M, Walley KR, Wood LD. Effect of lactic acidosis on canine hemodynamics and left ven-tricular function. Am J Physiol. 1990;258(4, pt 2):H1193-H1199.

39. Carlstedt F, Lind L, Rastad J, Stjernstrom H, Wide L, Ljunghall S. Parathyroid hormone and ionized calcium levels are related to the severity of illness and survival in critically ill patients. Eur J Clin Invest. 1998;28(11):898-903.

40. Lang RM, Fellner SK, Neumann A, Bushinsky DA, Borow KM. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med. 1988;108(4):524-529.

41. Cooper DJ, Walley KR, Dodek PM, Rosenberg F, Russell JA. Plasma ionized calcium and blood lactate concentrations are inversely associated in human lactic acidosis. Intensive Care Med. 1992;18(5):286-289.

42. Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med. 1990;112(7):492-498.

43. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1): 296-327.

44. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295(21):2511-2515.

45. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations.[erratum appears in Am J Cardiol. December 1, 2003;92(11):1378]. Am J Cardiol. 2003;91(9A):18F-40F.

46. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Circulation. 2003;108(3):367-372.

47. Chadda K, Annane D, Hart N, Gajdos P, Raphael JC, Lofaso F. Cardiac and respiratory effects of continuous positive airway pressure and noninvasive ventilation in acute cardiac pulmo-nary edema. Crit Care Med. 2002;30(11):2457-2461.

48. Gray AJ, Goodacre S, Newby DE, et al. A multicentre ran-domised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health Technol Assess. 2009;13(33):1-106.

49. Saia F, Grigioni F, Marzocchi A, Branzi A. Management of acute left ventricular dysfunction after primary percutaneous coro-nary intervention for ST elevation acute myocardial infarction. Am Heart J. 2010;160(6 suppl):S16-S21.

50. Kapur NK, Pham DT, Loyalka P. Percutaneous veno-arterial extracorporeal membrane oxygenation: another tool in the interventional-heart failure armamentarium. J Invasive Cardiol. 2010;22(8):370-371.

51. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-2150.

52. Plewka M, Krzeminska-Pakula M, Lipiec P, et al. Effect of intra-coronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am J Cardiol. 2009;104(10):1336-1342.

53. Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripo-tent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol. 2010;7(12):700-710.

54. Stein L, Beraud JJ, Morissette M, Luz PD, Weil MH, Shubin H. Pulmonary edema during volume infusion. Circulation. 1975;52(3):483-489.

55. de Simone G, Greco R, Mureddu G, et al. Relation of left ventricular diastolic properties to systolic function in arterial hypertension. Circulation. 2000;101(2):152-157.

56. Daneshvar D, Wei J, Tolstrup K, Thomson LE, Shufelt C, Merz CN. Diastolic dysfunction: improved understanding using emerging imaging techniques. Am Heart J. 2010;160(3): 394-404.

57. Paulus WJ. Novel strategies in diastolic heart failure. Heart. 2010;96(14):1147-1153.

58. Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004;350(13): 1320-1327.

59. Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomy-opathy.[see comment]. Circulation. 2000;101(21):2490-2496.

60. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107(19):2446-2452.


References 3

61. Moore TD, Frenneaux MP, Sas R, et al. Ventricular interaction and external constraint account for decreased stroke work dur-ing volume loading in CHF. Am J Physiol Heart Circ Physiol. 2001;281(6):H2385-H2391.

62. Miller RR, DeMaria AN, Amsterdam EA, et al. Improvement of reduced left ventricular diastolic compliance in ischemic heart disease after successful coronary artery bypass surgery. Am J Cardiol. 1975;35(1):11-16.

63. Walley KR, Cooper DJ. Diastolic stiffness impairs left ventricu-lar function during hypovolemic shock in pigs. Am J Physiol. 1991;260(3, pt 2):H702-H712.

64. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Advances in the understanding of pathogen-esis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113(3):227-242.

65. Russell JA, Ronco JJ, Lockhat D, Belzberg A, Kiess M, Dodek PM. Oxygen delivery and consumption and ventricular pre-load are greater in survivors than in nonsurvivors of the adult respiratory distress syndrome. Am Rev Respir Dis. 1990;141(3): 659-665.

66. Adamson PB, Kleckner KJ, VanHout WL, Srinivasan S, Abraham WT. Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure. Circulation. 2003;108(3):266-269.

67. Fox DJ, Tischenko A, Krahn AD, et al. Supraventricular tachycardia: diagnosis and management. Mayo Clin Proc. 2008;83(12):1400-1411.

68. Pierce WJ, McGroary K. Multifocal atrial tachycardia and Ibutilide. Am J Geriatr Cardiol. 2001;10(4):193-195.

69. Streeter DD Jr, Spotnitz HM, Patel DP, Ross J Jr, Sonnenblick EH. Fiber orientation in the canine left ventricle during diastole and systole. Circ Res. 1969;24(3):339-347.

70. Dell’Italia LJ, Walsh RA. Right ventricular diastolic pressure-volume relations and regional dimensions during acute altera-tions in loading conditions. Circulation. 1988;77(6):1276-1282.

71. Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest. 1997;111(1):218-224.

72. Poppas A, Rounds S. Congestive heart failure. Am J Respir Crit Care Med. 2002;165(1):4-8.

73. Eilen SD, Crawford MH, O’Rourke RA. Accuracy of precordial palpation for detecting increased left ventricular volume. Ann Intern Med. 1983;99(5):628-630.

74. Braunwald E. ACE inhibitors—a cornerstone of the treatment of heart failure. N Engl J Med. 1991;325(5):351-353.

75. Elliott P. Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy. Heart. 2000;84(1):106-112.

76. Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142(3):393-401.

77. Almeda FQ, Hollenberg SM. Update on therapy for acute and chronic heart failure. Applying advances in outpatient manage-ment. Postgrad Med. 2003;113(3):36-38, 41-44, 47-48.


Chapter 36

REFERENCES

1. Vos MA LB. Automaticity and Triggered Activity. Foundations of Cardiac Arrhythmias: Basic Concepts and Clinical Approaches. Marcel Dekker Inc; New York, NY. 2001:425-448.

2. Janse MJ, Dorinar E. Reentry. In: Spooner PM, Rosen MR, eds. Foundations of Cardiac Arrhythmias: Basic Concepts and Clinical Approaches. Marcel Dekker Inc; New York, NY. 2001:449-478

3. Zipes DP. Mechanisms of clinical arrhythmias. J Cardiovasc Electrophysiol. 2003;14(8):902-912.

4. Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart. 2000;84(3):339-346.

5. Members of the Sicilian Bambin. New approaches to antiarrhyth-mic therapy, part I: emerging therapeutic applications of the cell biology of cardiac arrhythmias. Circulation. 2001;104(23): 2865-2873.

6. Gillis AM. Class I antiarrhythmic drugs. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 4th ed. Philadelphia, PA: WB Sauders and Co; 2004:911-917.

7. Gillis AM. Proarrhythmia syndromes. In: Camm AJ, Saksena S, eds. Electrophysiological Disorders of the Heart. 2nd ed. Philadelphia, PA: WB Saunders and Co; 2004:501-516.

8. Dorian P. Mechanisms of action of class III agents and their clinical relevance. Europace. 2000;1(suppl C):C6-C9.

9. Pamukcu B, Lip GY. Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmaco-dynamics and clinical practice. Expert Opin Pharmacother. 2011;12(1):131-40.

10. Singh BN. β-blockers and calcium channel blockers as antiarrhythmic drugs. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 4th ed. Philadelphia, PA: WB Saunders and Co; 2004:918-9931.

11. Roden DM. Mechanisms and management of proarrhythmia. Am J Cardiol. 1998;82(4A):49I-57I.

12. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001: 933-970.

13. Wilkinson GR. Pharmacokinetics. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001:3-29.

14. Wadworth AN, Murdoch D, Brogden RN. Atenolol: a reap-praisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 1991;42(3):468-510.

15. McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure. Drugs. 2002;62(18):2677-2696.

16. Gillis AM, Wyse DG. Supraventricular tachycardia. In: Gray JD, ed. Therapeutic Choices. 4th ed. Ottawa, ON: Canadian Pharmacists Association; 2003:330-345.

17. Dorian P. Ventricular tachyarrhythmias. In: Gray JD, ed. Therapeutic Choices. 4th ed. Ottawa, ON: Canadian Pharmacists Association; 2003.

18. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11): 689-723.

19. Kannankeril PJ. Understanding drug-induced torsades de pointes: a genetic stance. Expert Opin Drug Saf. 2008;7(3): 231-239.

20. Myerburg RJ. Scientific gaps in the prediction and prevention of sudden cardiac death. J Cardiovasc Electrophysiol. 2002;13(7): 709-723.

21. Gillis AM, Hamilton RM, LeFeuvre CA. Unusual causes of sud-den cardiac death due to ventricular tachyarrhythmias. Can J Cardiol. 2000;16(suppl C):34C-40C.

22. Connolly SJ, Krahn A, Klein G. Long term management of the survivor of ventricular fibrillation or sustained ventricular tachycardia. Can J Cardiol. 2000;16(suppl C):20C-22C.

23. Grogin HR, Scheinman M. Evaluation and management of patients with polymorphic ventricular tachycardia. Cardiol Clin. 1993;11(1):39-54.

24. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecu-lar characterization of patients with catecholaminergic polymor-phic ventricular tachycardia. Circulation. 2002;106(1):69-74.

25. Gillis AM. Intractable ventricular arrhythmias: immediate evaluation and management, role of pharmacological therapy. Card Electrophysiol Rev. 2001;3(2):145-148.

26. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Asso-ciation Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 suppl 3):S729-S767.

27. Link MS, Atkins DL, Passman RS, et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 suppl 3):S706-S719.


References2

28. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000;102(7):742-747.

29. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prog-nostic implications. J Am Coll Cardiol. 1998;32(7):1909-1915.

30. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynami-cally destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995;92(11):3255-3263.

31. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. Arandomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882-1890.

32. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implant-able cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237.

33. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883.

34. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resusci-tated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576-1583.

35. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implant-able cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297-1302.

36. Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2011;8(6):864-871.

37. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77(2): 392-397.

38. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol. 2000;11(5):593-600.

39. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary preven-tion trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071-2078.

40. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrilla-tion—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906.

41. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the manage-ment of atrial fibrillation: the task force for the management of

atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.

42. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666.

43. Chauhan VS, Krahn AD, Klein GJ, Skanes AC, Yee R. Supraventricular tachycardia. Med Clin North Am. 2001;85(2):193-223, ix.

44. Gillis AM, Verma A, Talajic M, Nattel S, Dxorian P. Canadian cardiovascular society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol. 2011;27(1):47-59.

45. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-1373.

46. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian cardiovascular society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27(1):74-90.

47. Kochiadakis GE, Igoumenidis NE, Simantirakis EN, et al. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. Pacing Clin Electrophysiol. 1998;21(11 Pt 2): 2475-2479.

48. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.

49. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent per-sistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-1840.

50. Newman D, Gillis A, Gilbert M, Dorian P. Long term drug therapy for the prevention of recurrence in atrial fibrillation. Can J Cardiol. 1996;12(suppl A):21A-26A.

51. Patel C, Yan GX, Kowey PR. Dronedarone. Circulation. 2009;120(7):636-644.

52. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mor-tality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-412.

53. Waldo AL, Camm AJ, deRuyter H, et al. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral D-Sotalol. Lancet. 1996;348(9019):7-12.

54. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101(10):1138-1144.

55. Jais P, Weerasooriya R, Shah DC, et al. Ablation therapy for atrial fibrillation (AF): past, present and future. Cardiovasc Res. 2002;54(2):337-346.

56. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501.

57. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran ver-sus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.

58. Yee R, Connolly S, Noorani H. Clinical review of radiofre-quency catheter ablation for cardiac arrhythmias. Can J Cardiol. 2003;19(11):1273-1284.


References 3

59. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. Heart Rhythm. 2008;5(6):934-955.

60. Bernstein AK, Parsonnet V. Pacemaker, defibrillator, and lead codes. In: Ellenbogen KA, Kay GN, Lau CP, Wilkoff B, eds. Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2007: 279-287.

61. Bernstein AD, Daubert JC, Fletcher RD, et al. The revised NASPE/BPEG generic code for antibradycardia, adaptive-rate, and multisite pacing. North American Society of Pacing and Electrophysiology/British Pacing and Electrophysiology Group. Pacing Clin Electrophysiol. 2002;25(2):260-264.

62. Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pac-ing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000;342(19):1385-1391.

63. Lamas GA, Lee K, Sweeney M, et al. The mode selection trial (MOST) in sinus node dysfunction: design, rationale, and baseline characteristics of the first 1000 patients. Am Heart J. 2000;140(4):541-551.

64. Gillis AM. Redefining physiologic pacing: lessons learned from recent clinical trials. Heart Rhythm. 2006;3(11):1367-1372.

65. Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pac-ing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000;342(19):1385-1391.

66. Gillis AM, Philippon F, Cassidy MR, et al. Guidelines for implantable cardioverter defibrillator follow-up in Canada: a consensus statement of the Canadian Working Group on Cardiac Pacing. Can J Cardiol. 2003;19(1):21-37.

67. Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable elec-tronic devices (CIEDs): description of techniques, indications,

personnel, frequency and ethical considerations. Heart Rhythm. 2008;5(6):907-925.

68. Fraser JD, Gillis AM, Irwin ME, Nishimura S, Tyers GF, Philippon F. Guidelines for pacemaker follow-up in Canada: a consensus statement of the Canadian Working Group on Cardiac Pacing. Can J Cardiol. 2000;16(3):355-376.

69. Chapa DW, Lee HJ, Kao CW, et al. Reducing mortality with device therapy in heart failure patients without ventricular arrhythmias. Am J Crit Care. 2008;17(5):443-452.

70. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385-95.

71. Gillis AM, Fast VG, Rohr S, Kleber AG. Spatial changes in trans-membrane potential during extracellular electrical shocks in cultured monolayers of neonatal rat ventricular myocytes. Circ Res. 1996;79(4):676-690.

72. Bardy GH, Marchlinski FE, Sharma AD et al. Multicenter comparison of truncated biphasic shocks and standard damped sine wave monophasic shocks for transthoracic ven-tricular defibrillation. Transthoracic Investigators. Circulation. 1996;94(10):2507-2514.

73. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933-1940.

74. Goldenberg I, Gillespie J, Moss AJ, et al. Long-term ben-efit of primary prevention with an implantable cardioverter- defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation. 2010;122(13):1265-1271.

75. Swygman C, Wang PJ, Link MS, Homoud MK, Estes NA, III. Advances in implantable cardioverter defibrillators. Curr Opin Cardiol. 2002;17(1):24-28.


Chapter 37

REFERENCES

1. Braunwald E. Control of myocardial oxygen consump-tion. Physiologic and clinical considerations. Am J Cardiol. 1971;27:416-432.

2. Sherman CT, Litvack F, Grundfest W, et al. Coronary angios-copy in patients with unstable angina pectoris. N Engl J Med. 1986;315:913-919.

3. Croft CH, Nicod P, Corbett JR, et al. Detection of acute right ventricular infarction by right precordial electrocardiography. Am J Cardiol. 1982;50:421-427.

4. Spodick DH. Diagnostic electrocardiographic sequences in acute pericarditis. Significance of PR segment and PR vector changes. Circulation. 1973;48:575-580.

5. Pepine CJ. Silent myocardial ischemia: definition, magnitude, and scope of the problem. Cardiol Clin. 1986;4:577-581.

6. Upton MT, Rerych SK, Newman GE, Port S, Cobb FR, Jones RH. Detecting abnormalities in left ventricular function during exercise before angina and ST-segment depression. Circulation. 1980;62:341-349.

7. Sugishita Y, Koseki S, Matsuda M, Tamura T, Yamaguchi I, Ito I. Dissociation between regional myocardial dysfunction and ECG changes during myocardial ischemia induced by exercise in patients with angina pectoris. Am Heart J. 1983;106:1-8.

8. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac dis-ease: the present and the future. J Am Coll Cardiol. 2006;48:1-11.

9. Fromm RE Jr. Cardiac troponins in the intensive care unit: common causes of increased levels and interpretation. Crit Care Med. 2007;35:584-588.

10. Wu AH. Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? Intensive Care Med. 2001;27:959-961.

11. Kaul S, Stratienko AA, Pollock SG, Marieb MA, Keller MW, Sabia PJ. Value of two-dimensional echocardiography for deter-mining the basis of hemodynamic compromise in critically ill patients: a prospective study. J Am Soc Echocardiogr. 1994;7: 598-606.

12. Feigenbaum H, Corya BC, Dillon JC, et al. Role of echocardiog-raphy in patients with coronary artery disease. Am J Cardiol. 1976;37:775-786.

13. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med. 1999;131:47-59.

14. Nishimura RA, Tajik AJ, Shub C, Miller FA Jr, Ilstrup DM, Harrison CE. Role of two-dimensional echocardiography in the

prediction of in-hospital complications after acute myocardial infarction. J Am Coll Cardiol. 1984;4:1080-1087.

15. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134:479-487.

16. Reilly JP, Tunick PA, Timmermans RJ, Stein B, Rosenzweig BP, Kronzon I. Contrast echocardiography clarifies uninterpretable wall motion in intensive care unit patients. J Am Coll Cardiol. 2000;35:485-490.

17. Hollenberg SM, Parrillo JE. Shock. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison’s Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill; 1997: 214-222.

18. Nedeljkovic ZS, Ryan TJ. Right ventricular infarction. In: Hollenberg SM, Bates ER, eds. Cardiogenic Shock. Armonk, NY: Futura Publishing Company; 2002:161-186.

19. Hansen RM, Viquerat CE, Matthay MA, et al. Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary aftery bypass graft surgery. Anesthesiology. 1986;64:764-770.

20. Hollenberg SM. Recognition and treatment of cardiogenic shock. Semin Respir Crit Care Med. 2004;25:661-671.

21. Craven L. Experience with aspirin (acetysalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Miss Vlly Med J. 1953;75:38-44.

22. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med. 1989;321:129-135.

23. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for preven-tion of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;342:71-86.

24. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336: 973-979.

25. Cohn PF, Gorlin R. Physiologic and clinical actions of nitroglyc-erin. Med Clin North Am. 1974;58:407-415.

26. Frishman WH. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation. 1983;67:I11-I18.


References2

27. Oliva PB, Potts DE, Pluss RG. Coronary arterial spasm in Prinzmetal angina. Documentation by coronary arteriography. N Engl J Med. 1973;288:745-751.

28. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-con-verting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.

29. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the man-agement of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007;116: 2762-2772.

30. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.

31. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk fac-tors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.

32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.

33. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.

34. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.

35. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.

36. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.

37. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guide-line update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003;107:149-158.

38. Ferguson JJ III, Cohen M, Freedman RJ Jr, et al. The cur-rent practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. J Am Coll Cardiol. 2001;38: 1456-1462.

39. Gewirtz H, Ohley W, Williams DO, Sun Y, Most AS. Effect of intraaortic balloon counterpulsation on regional myocardial blood flow and oxygen consumption in the presence of coro-nary artery stenosis: observations in an awake animal model. Am J Cardiol. 1982;50:829-837.

40. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute

myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890-911.

41. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271-2306.

42. Go AS, Barron HV, Rundle AC, Ornato JP, Avins AL. Bundle-branch block and in-hospital mortality in acute myocar-dial infarction. National Registry of Myocardial Infarction 2 Investigators. Ann Intern Med. 1998;129:690-697.

43. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombo-lytic treatment in acute myocardial infarction. Lancet. 1986;1: 397-402.

44. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312: 932-936.

45. TIMI Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Circulation. 1994;89:1545-1556.

46. GUSTO Investigators. An international randomized trial com-paring four thrombolytic strategies for acute myocardial infarc-tion. N Engl J Med. 1993;329:673-682.

47. GUSTO Angiographic Investigators. The effects of tissue plas-minogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocar-dial infarction. N Engl J Med. 1993;329:1615-1622.

48. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.

49. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716-722.

50. Grines CL, Browne KF, Marco J, et al. A comparison of immedi-ate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993;328:673-679.

51. GUSTO IIb Investigators. A comparison of recombinant hiru-din with heparin for the treatment of acute coronary syn-dromes. N Engl J Med. 1996;335:775-782.

52. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J. 2003;145:47-457.

53. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarc-tion: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.


References 3

54. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocar-dial infarction. JAMA. 2000;283:2941-2497.

55. Schroder R, Dissmann R, Bruggemann T, et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24:384-391.

56. Anderson RD, White HD, Ohman EM, et al. Predicting out-come after thrombolysis in acute myocardial infarction accord-ing to ST-segment resolution at 90 minutes: a substudy of the GUSTO III trial. Am Heart J. 2002;144:81-88.

57. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med. 1999;341:1957-1965.

58. Stone GW, Brodie BR, Griffin JJ, et al. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 1999;99:1548-1554.

59. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous strep-tokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.

60. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931-938.

61. Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynam-ics of clopidogrel. Semin Thromb Hemost. 1999;25(suppl 2):3-8.

62. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopido-grel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.

63. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopido-grel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294: 1224-1232.

64. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implica-tions, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516.

65. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic deter-minants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.

66. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutane-ous coronary intervention. The GRAVITAS randomized trial. JAMA. 2011;305:1097-1105.

67. Michelson AD, Frelinger AL 3rd, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasu-grel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30:1753-1763.

68. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:e9-e16.

69. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.

70. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: ran-domised placebo-controlled trial. Lancet. 2005;366:1607-1621.

71. Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol. 2000;36:2028-2035.

72. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 1999;341:319-327.

73. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. Lancet. 1998;352:87-92.

74. Montalescot G, Barragan P, Wittenberg O, et al. Platelet gly-coprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.

75. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.

76. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergo-ing primary percutaneous coronary intervention after clopi-dogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933-1940.

77. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.

78. Van’t Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double- blind, randomised controlled trial. Lancet. 2008;372:537-546.

79. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the manage-ment of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51:210-247.

80. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696-703.

81. Mehran R, Brodie B, Cox DA, et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J. 2008;156:44-56.

82. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-1159.

83. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin ver-sus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477-1488.


References4

84. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Fibrinolytic Regimen (ASSENT)-3 PLUS random-ized trial in acute myocardial infarction. Circulation. 2003;108: 135-142.

85. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519-1530.

86. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cariol. 2007;50:1742-1751.

87. Gruppo Italiano per lo Studio della Sopravvinza nell’Infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transder-mal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115-1122.

88. ISIS-4 (Fourth International Study of Infarct Survival) Study Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sul-phate in 58,050 patients with suspected acute myocardial infarc-tion. Lancet. 1995;345:669-685.

89. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57-66.

90. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the throm-bolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med. 1989;320:618-627.

91. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarc-tion: randomised placebo-controlled trial. Lancet. 2005;366: 1622-1632.

92. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled interna-tional trial. Eur Heart J. 1985;6:199-226.

93. The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med. 1984;310:9-15.

94. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.

95. CONSENSUS Trial Study Group. Effects of enalapril on mortal-ity in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.

96. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.

97. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.

98. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327: 669-677.

99. Edner M, Bonarjee VV, Nilsen DW, Berning J, Carstensen S, Caidahl K. Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with refer-ence to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group. Clin Cardiol. 1996;19: 543-548.

100. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarc-tion in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986;315:423-429.

101. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA. 1988;260:1910-1916.

102. Lauler DP. Magnesium—coming of age. Am J Cardiol. 1989;63:1g-3g.

103. Braunwald E. Unstable angina. A classification. Circulation. 1989;80:410-414.

104. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med. 1996;335:133-1341.

105. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396-403.

106. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313:1369-1375.

107. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.

108. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.

109. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sus-tained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.

110. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.

111. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopi-dogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.

112. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;116:803-877.

113. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.


References 5

114. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811-815.

115. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447-452.

116. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the throm-bolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601.

117. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602-1608.

118. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospec-tive randomised multicentre study. Lancet. 1999;354:708-715.

119. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and pro-visional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percuta-neous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.

120. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina. N Engl J Med. 1998;338:1498-1505.

121. The PURSUIT Trial Investigators. Inhibition of platelet glyco-protein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.

122. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349:1429-1435.

123. Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction ran-domly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 1998;338:1785-1792.

124. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.

125. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360:743-751.

126. Hirsch A, Windhausen F, Tijssen JG, Verheugt FW, Cornel JH, de Winter RJ. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST- elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet. 2007;369:827-835.

127. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165-2175.

128. Reardon MJ, Carr CL, Diamond A, et al. Ischemic left ventricu-lar free wall rupture: prediction, diagnosis, and treatment. Ann Thorac Surg. 1997;64:1509-1513.

129. Killen DA, Piehler JM, Borkon AM, Gorton ME, Reed WA. Early repair of postinfarction ventricular septal rupture. Ann Thorac Surg. 1997;63:138-142.

130. Khan SS, Gray RJ. Valvular emergencies. Cardiol Clin. 1991;9:689-709.

131. Bolooki H. Emergency cardiac procedures in patients in car-diogenic shock due to complications of coronary artery disease. Circulation. 1989;79:I137-I148.

132. Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol. 2008;52:319-326.

133. Zehender M, Kasper W, Kauder E, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med. 1993;328: 981-988.

134. Dell’Italia LJ, Starling MR, Blumhardt R, Lasher JC, O’Rourke RA. Comparative effects of volume loading, dobutamine, and nitro-prusside in patients with predominant right ventricular infarc-tion. Circulation. 1985;72:1327-1335.

135. Bowers TR, O’Neill WW, Grines C, Pica MC, Safian RD, Goldstein JA. Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J Med. 1998;338:933-940.

136. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicat-ing acute myocardial infarction. N Engl J Med. 1999;340: 1162-1168.

137. Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. Circulation. 1995;91:873-881.

138. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995;26:668-674.

139. De Backer D, Biston P, Devriendt J, et al. Comparison of dopa-mine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779-789.

140. Hollenberg SM, Hoyt JW. Pulmonary artery catheters in cardio-vascular disease. New Horizons. 1997;5:207-213.

141. Russ MA, Prondzinsky R, Christoph A, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med. 2007;35:2732-2739.

142. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ, Abreu-Gonzalez P, Munoz MB. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosi-mendan compared with dobutamine on haemodynamics. Eur J Heart Failure. 2006;8:723-728.

143. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297: 1883-1891.

144. Willerson JT, Curry GC, Watson JT, et al. Intraaortic balloon counterpulsation in patients in cardiogenic shock, medically


References6

refractory left ventricular failure and/or recurrent ventricular tachycardia. Am J Med. 1975;58:183-191.

145. Bates ER, Stomel RJ, Hochman JS, Ohman EM. The use of intraaortic balloon counterpulsation as an adjunct to reperfu-sion therapy in cardiogenic shock. Int J Cardiol. 1998;65(suppl 1): S37-S42.

146. Gruppo Italiano per lo Studio Della Streptochinasi Nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;2:397-402.

147. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thromboly-sis, intra-aortic balloon pump counterpulsation, and their com-bination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000;36:1123-1129.

148. Becker RC. Hemodynamic, mechanical, and metabolic deter-minants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with car-diogenic shock. Am Heart J. 1993;125:919-929.

149. Garber PJ, Mathieson AL, Ducas J, Patton JN, Geddes JS, Prewitt RM. Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration. Can J Cardiol. 1995;11:30-36.

150. Berger PB, Holmes DR Jr., Stebbins AL, Bates ER, Califf RM, Topol EJ. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation. 1997;96:122-127.

151. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056-2063.

152. Hochman JS, Sleeper LA, Webb JG, et al. Early revasculariza-tion in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341:625-634.

153. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190-192.

154. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myo-cardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J. 1999;20:1030-1038.


Chapter 38

REFERENCES

1. Redington AN, Gray HH, Hodson ME, et al. Characterisation of the normal right ventricular pressure-volume relation by biplane angiography and simultaneous micromanometer pres-sure measurements. Br Heart J. 1988;59:23-30.

2. Cross CE. Right ventricular pressure and coronary flow. Am J Physiol. 1962;202:12-16.

3. Reiser PJ, Portman MA, Ning XH, et al. Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ven-tricles. Am J Physiol Heart Circ Physiol. 2001;280:H1814-H1820.

4. Wang GY, McCloskey DT, Turcato S, et al. Contrasting inotro-pic responses to alpha1-adrenergic receptor stimulation in left versus right ventricular myocardium. Am J Physiol Heart Circ Physiol. 2006;291:H2013-H2017.

5. Piazza G, Goldhaber SZ. The acutely decompensated right ventricle: pathways for diagnosis and management. Chest. 2005;128:1836-1852.

6. Redington AN. Right ventricular function. Cardiol Clin. 2002;20:341-349, v.

7. Yerebakan C, Klopsch C, Niefeldt S, et al. Acute and chronic response of the right ventricle to surgically induced pressure and volume overload—an analysis of pressure-volume relations. Interact Cardiovasc Thorac Surg. 2010;10:519-525.

8. Modesti PA, Vanni S, Bertolozzi I, et al. Different growth factor activation in the right and left ventricles in experimental vol-ume overload. Hypertension. 2004;43:101-108.

9. Quaife RA, Lynch D, Badesch DB, et al. Right ventricular phe-notypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy. J Card Fail. 1999;5:46-54.

10. Jardin F, Dubourg O, Gueret P, et al. Quantitative two-dimen-sional echocardiography in massive pulmonary embolism: emphasis on ventricular interdependence and leftward septal displacement. J Am Coll Cardiol. 1987;10:1201-1206.

11. Jardin F, Vieillard-Baron A. Acute cor pulmonale. Curr Opin Crit Care. 2009;15:67-70.

12. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmo-nary disease. Am J Cardiol. 1971;28:288-294.

13. Scharf S, Warner K, Josa M, et al. Load tolerance of the right ventricle: effect of increased aortic pressure. J Crit Care. 1986;1:163-173.

14. Molloy WD, Lee KY, Girling L, et al. Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis. 1984;130:870-874.

15. Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation. 2002;106:1263-1268.

16. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratifica-tion of patients with acute pulmonary embolism. Circulation. 2003;108:2191-2194.

17. Roncon-Albuquerque R Jr, Vasconcelos M, Lourenco AP, et al. Acute changes of biventricular gene expression in volume and right ventricular pressure overload. Life Sci. 2006;78:2633-2642.

18. Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest. 1991;100:598-603.

19. Xu J, Durand LG, Pibarot P. A new, simple, and accurate method for non-invasive estimation of pulmonary arterial pressure. Heart. 2002;88:76-80.

20. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83:416-420.

21. Ceriani E, Combescure C, Le Gal G, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:957-970.

22. Stein PD, Athanasoulis C, Alavi A, et al. Complications and validity of pulmonary angiography in acute pulmonary embo-lism. Circulation. 1992;85:462-468.

23. Sreeram N, Cheriex EC, Smeets JL, et al. Value of the 12-lead electrocardiogram at hospital admission in the diagnosis of pulmonary embolism. Am J Cardiol. 1994;73:298-303.

24. Kanne JP, Lalani TA. Role of computed tomography and mag-netic resonance imaging for deep venous thrombosis and pul-monary embolism. Circulation. 2004;109:I15-I21.

25. Gulsun M, Goodman LR. CT for the diagnosis of venous thromboembolic disease. Curr Opin Pulm Med. 2003;9:367-373.

26. MacDonald SL, Mayo JR. Computed tomography of acute pul-monary embolism. Semin Ultrasound CT MR. 2003;24:217-231.

27. Enden T, Klow NE. CT pulmonary angiography and suspected acute pulmonary embolism. Acta Radiol. 2003;44:310-315.


References2

28. Remy-Jardin M, Mastora I, Remy J. Pulmonary embolus imag-ing with multislice CT. Radiol Clin North Am. 2003;41:507-519.

29. Schoepf UJ, Costello P. Multidetector-row CT imaging of pul-monary embolism. Semin Roentgenol. 2003;38:106-114.

30. Contractor S, Maldjian PD, Sharma VK, et al. Role of helical CT in detecting right ventricular dysfunction secondary to acute pulmonary embolism. J Comput Assist Tomogr. 2002;26: 587-591.

31. Mertens LL, Friedberg MK. Imaging the right ventricle— current state of the art. Nat Rev Cardiol. 2010;7:551-563.

32. Vieillard-Baron A, Prin S, Chergui K, et al. Echo-Doppler dem-onstration of acute cor pulmonale at the bedside in the medi-cal intensive care unit. Am J Respir Crit Care Med. 2002;166: 1310-1319.

33. Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998;339: 93-104.

34. Chartier L, Bera J, Delomez M, et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation. 1999;99:2779-2783.

35. Troughton RW, Prior DL, Pereira JJ, et al. Plasma B-type natri-uretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol. 2004;43:416-422.

36. Horton KD, Meece RW, Hill JC. Assessment of the right ven-tricle by echocardiography: a primer for cardiac sonographers. J Am Soc Echocardiogr. 2009;22:776-792;quiz 861-772.

37. Kasper W, Meinertz T, Kerstin F, et al. Echocardiography in assessing acute pulmonary hypertension due to pulmonary embolism. Am J Cardiol. 1980;45:567-572.

38. Vieillard-Baron A, Qanadli SD, Antakly Y, et al. Transesophageal echocardiography for the diagnosis of pulmonary embolism with acute cor pulmonale: a comparison with radiological pro-cedures. Intensive Care Med. 1998;24:429-433.

39. Jardin F, Dubourg O, Bourdarias JP. Echocardiographic pattern of acute cor pulmonale. Chest. 1997;111:209-217.

40. Bommer W, Weinert L, Neumann A, et al. Determination of right atrial and right ventricular size by two-dimensional echo-cardiography. Circulation. 1979;60:91-100.

41. Rydman R, Soderberg M, Larsen F, et al. Echocardiographic evaluation of right ventricular function in patients with acute pulmonary embolism: a study using tricuspid annular motion. Echocardiography. 2010;27:286-293.

42. Meris A, Faletra F, Conca C, et al. Timing and magnitude of regional right ventricular function: a speckle tracking-derived strain study of normal subjects and patients with right ventricu-lar dysfunction. J Am Soc Echocardiogr. 2010;23:823-831.

43. Shimada YJ, Shiota M, Siegel RJ, et al. Accuracy of right ventric-ular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr. 2010;23: 943-953.

44. Hein M, Roehl AB, Baumert JH, et al. Continuous right ven-tricular volumetry by fast-response thermodilution during right ventricular ischemia: head-to-head comparison with conductance catheter measurements. Crit Care Med. 2009;37: 2962-2967.

45. Vieillard-Baron A, Page B, Augarde R, et al. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic

pattern, clinical implications and recovery rate. Intensive Care Med. 2001;27:1481-1486.

46. Mekontso Dessap A, Boissier F, Leon R, et al. Prevalence and prognosis of shunting across patent foramen ovale during acute respiratory distress syndrome. Crit Care Med. 2010;38: 1786-1792.

47. Serrano CV, Ramires JA, Cesar LA, et al. Prognostic significance of right ventricular dysfunction in patients with acute inferior myocardial infarction and right ventricular involvement. Clin Cardiol. 1995;18:199-205.

48. Cohn JN, Guiha NH, Broder MI, et al. Right ventricular infarction. Clinical and hemodynamic features. Am J Cardiol. 1974;33:209-214.

49. Goldstein JA. Right heart ischemia: pathophysiology, natu-ral history, and clinical management. Prog Cardiovasc Dis. 1998;40:325-341.

50. Goldstein JA, Tweddell JS, Barzilai B, et al. Right atrial isch-emia exacerbates hemodynamic compromise associated with experimental right ventricular dysfunction. J Am Coll Cardiol. 1991;18:1564-1572.

51. Chiladakis JA, Patsouras N, Manolis AS. The Bezold-Jarisch reflex in acute inferior myocardial infarction: clinical and sym-pathovagal spectral correlates. Clin Cardiol. 2003;26:323-328.

52. Hamon M, Agostini D, Le Page O, et al. Prognostic impact of right ventricular involvement in patients with acute myocardial infarction: meta-analysis. Crit Care Med. 2008;36:2023-2033.

53. Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK regis-try. J Am Coll Cardiol. 2003;41:1273-1279.

54. Lupi-Herrera E, Lasses LA, Cosio-Aranda J, et al. Acute right ventricular infarction: clinical spectrum, results of reperfu-sion therapy and short-term prognosis. Coron Artery Dis. 2002;13:57-64.

55. Monchi M, Bellenfant F, Cariou A, et al. Early predictive factors of survival in the acute respiratory distress syndrome: a multi-variate analysis. Am J Respir Crit Care Med. 1998;158:1076-1081.

56. Squara P, Dhainaut JF, Artigas A, et al. Hemodynamic profile in severe ARDS: results of the European Collaborative ARDS Study. Intensive Care Med. 1998;24:1018-1028.

57. Abroug F, Ouanes-Besbes L, Dachraoui F, et al. An updated study-level meta-analysis of randomised controlled trials on proning in ARDS and acute lung injury. Crit Care. 2011;15:R6.

58. Gattinoni L, Carlesso E, Taccone P, et al. Prone position-ing improves survival in severe ARDS: a pathophysiologic review and individual patient meta-analysis. Minerva Anestesiol. 2010;76:448-454.

59. Vieillard-Baron A, Charron C, Caille V, et al. Prone posi-tioning unloads the right ventricle in severe ARDS. Chest. 2007;132:1440-1446.

60. Dehring DJ, Fader RC, Traber LD, et al. Cardiopulmonary changes occurring with pulmonary intravascular clearance of live bacteria in sheep. Circ Shock. 1989;29:245-256.

61. Reuse C, Frank N, Contempre B, et al. Right ventricular func-tion in septic shock. Intensive Care Med. 1988;14(suppl 2): 486-487.

62. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth. 2001;15:364-376.


References 3

63. Carlson DL, Willis MS, White DJ, et al. Tumor necrosis factor-alpha-induced caspase activation mediates endotoxin-related cardiac dysfunction. Crit Care Med. 2005;33:1021-1028.

64. Schneider AJ, Teule GJ, Groeneveld AB, et al. Biventricular performance during volume loading in patients with early septic shock, with emphasis on the right ventricle: a combined hemodynamic and radionuclide study. Am Heart J. 1988;116: 103-112.

65. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, ran-domized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21-30.

66. Machado RF, Mack AK, Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol. 2007;136:319-325.

67. Mekontso Dessap A, Leon R, Habibi A, et al. Pulmonary hyper-tension and cor pulmonale during severe acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2008;177: 646-653.

68. Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol. 2010;85:800-802.

69. Sullivan KJ, Goodwin SR, Evangelist J, et al. Nitric oxide suc-cessfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med. 1999;27:2563-2568.

70. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002;21:232-244.

71. Khan TA, Bianchi C, Araujo EG, et al. Activation of pulmonary mitogen-activated protein kinases during cardiopulmonary bypass. J Surg Res. 2003;115:56-62.

72. Bond BR, Dorman BH, Clair MJ, et al. Endothelin-1 during and after cardiopulmonary bypass: association to graft sensi-tivity and postoperative recovery. J Thorac Cardiovasc Surg. 2001;122:358-364.

73. Fullerton DA, Jones SD, Grover FL, et al. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg. 1996;61:1118-1123; discussion 1114-1123.

74. Beck JR, Mongero LB, Kroslowitz RM, et al. Inhaled nitric oxide improves hemodynamics in patients with acute pulmo-nary hypertension after high-risk cardiac surgery. Perfusion. 1999;14:37-42.

75. Miller OI, Tang SF, Keech A, et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congeni-tal heart surgery: a randomised double-blind study. Lancet. 2000;356:1464-1469.

76. Lyons JM, Duffy JY, Wagner CJ, et al. Sildenafil citrate alleviates pulmonary hypertension after hypoxia and reoxygenation with cardiopulmonary bypass. J Am Coll Surg. 2004;199:607-614.

77. Theodoraki K, Rellia P, Thanopoulos A, et al. Inhaled ilo-prost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth. 2002;49:963-967.

78. Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth. 2008;22:406-413.

79. Mahler DA, Brent BN, Loke J, et al. Right ventricular perfor-mance and central circulatory hemodynamics during upright

exercise in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1984;130:722-729.

80. Akgul F, Batyraliev T, Karben Z, et al. Effects of acute hypoxia on left and right ventricular contractility in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007;2: 77-80.

81. Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol. 2009;104:1300-1306.

82. Tugcu A, Guzel D, Yildirimturk O, et al. Evaluation of right ventricular systolic and diastolic function in patients with newly diagnosed obstructive sleep apnea syndrome without hyperten-sion. Cardiology. 2009;113:184-192.

83. Haddad F, Peterson T, Fuh E, et al. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail. 2011;4: 692-699.

84. Hoeper MM, Granton J. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. Am J Respir Crit Care Med. 2011;184:1114-1124.

85. Price LC, Wort SJ, Finney SJ, et al. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care. 2010;14:R169.

86. Mebazaa A, Karpati P, Renaud E, et al. Acute right ventricular failure—from pathophysiology to new treatments. Intensive Care Med. 2004;30:185-196.

87. Kakouros N, Cokkinos DV. Right ventricular myocardial infarc-tion: pathophysiology, diagnosis, and management. Postgrad Med J. 2010;86:719-728.

88. Belenkie I, Dani R, Smith ER, et al. Effects of volume loading during experimental acute pulmonary embolism. Circulation. 1989;80:178-188.

89. Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output compli-cating an acute increase in right ventricular afterload in dogs. Anesthesiology. 1984;60:132-135.

90. Dell’Italia LJ, Starling MR, Blumhardt R, et al. Comparative effects of volume loading, dobutamine, and nitroprusside in patients with predominant right ventricular infarction. Circulation. 1985;72:1327-1335.

91. Ferrario M, Poli A, Previtali M, et al. Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarction. Am J Cardiol. 1994;74:329-333.

92. Mahjoub Y, Pila C, Friggeri A, et al. Assessing fluid respon-siveness in critically ill patients: false-positive pulse pressure variation is detected by Doppler echocardiographic evaluation of the right ventricle. Crit Care Med. 2009;37:2570-2575.

93. Kim YK, Shin WJ, Song JG, et al. Effect of right ventricular dysfunction on dynamic preload indices to predict a decrease in cardiac output after inferior vena cava clamping during liver transplantation. Transplant Proc. 2010;42:2585-2589.

94. Bates ER, Crevey BJ, Sprague FR, et al. Oral hydralazine therapy for acute pulmonary embolism and low output state. Arch Intern Med. 1981;141:1537-1538.

95. Calvin JE. The role of ventricular interaction in critical illness. Update in Intensive Care and Emergency Medicine. 1990;10: 305-317.


References4

96. Cockrill BA, Kacmarek RM, Fifer MA, et al. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemo-dynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest. 2001;119:128-136.

97. Angle MR, Molloy DW, Penner B, et al. The cardiopulmonary and renal hemodynamic effects of norepinephrine in canine pulmonary embolism. Chest. 1989;95:1333-1337.

98. Boulain T, Lanotte R, Legras A, et al. Efficacy of epinephrine therapy in shock complicating pulmonary embolism. Chest. 1993;104:300-302.

99. Vlahakes GJ, Turley K, Hoffman JI. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation. 1981;63:87-95.

100. Hirsch LJ, Rooney MW, Wat SS, et al. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest. 1991;100: 796-801.

101. Ducas J, Stitz M, Gu S, et al. Pulmonary vascular pressure-flow characteristics. Effects of dopamine before and after pulmonary embolism. Am Rev Respir Dis. 1992;146:307-312.

102. Wasson S, Govindarajan G, Reddy HK, et al. The role of nitric oxide and vasopressin in refractory right heart failure. J Cardiovasc Pharmacol Ther. 2004;9:9-11.

103. Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med. 2002;30:2548-2552.

104. Jardin F, Genevray B, Brun-Ney D, et al. Dobutamine: a hemo-dynamic evaluation in pulmonary embolism shock. Crit Care Med. 1985;13:1009-1012.

105. Bradford KK, Deb B, Pearl RG. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pul-monary hypertension in the rabbit. J Cardiovasc Pharmacol. 2000;36:146-151.

106. Pagnamenta A, Fesler P, Vandinivit A, et al. Pulmonary vascular effects of dobutamine in experimental pulmonary hyperten-sion. Crit Care Med. 2003;31:1140-1146.

107. Wolfe MW, Saad RM, Spence TH. Hemodynamic effects of amrinone in a canine model of massive pulmonary embolism. Chest. 1992;102:274-278.

108. Kihara S, Kawai A, Fukuda T, et al. Effects of milrinone for right ventricular failure after left ventricular assist device implanta-tion. Heart Vessels. 2002;16:69-71.

109. Kerbaul F, Rondelet B, Demester JP, et al. Effects of levosimen-dan versus dobutamine on pressure load-induced right ven-tricular failure. Crit Care Med. 2006;34:2814-2819.

110. Kerbaul F, Gariboldi V, Giorgi R, et al. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med. 2007;35:1948-1954.

111. Melot C, Lejeune P, Leeman M, et al. Prostaglandin E1 in the adult respiratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis. 1989;139:106-110.

112. Bolliger C, Fourie P, Coetzee A. The effect of prostaglandin E1 on acute pulmonary artery hypertension during oleic acid-induced respiratory dysfunction. Chest. 1991;99:1501-1506.

113. Rossaint R, Slama K, Steudel W, et al. Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. Intensive Care Med. 1995;21:197-203.

114. Fierobe L, Brunet F, Dhainaut JF, et al. Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151:1414-1419.

115. Kaisers U, Busch T, Deja M, et al. Selective pulmonary vasodi-lation in acute respiratory distress syndrome. Crit Care Med. 2003;31:S337-S342.

116. Solina A, Papp D, Ginsberg S, et al. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth. 2000;14:12-17.

117. Lundin S, Mang H, Smithies M, et al. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. 1999;25:911-919.

118. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998; 26:15-23.

119. Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a ran-domized controlled trial. JAMA. 2004;291:1603-1609.

120. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med. 1998;157:1483-1488.

121. Levy B, Perez P, Perny J, et al. Comparison of norepinephrine-dobu-tamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med. 2011;39(3):455-455.

122. Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hyperten-sion. Eur Respir J. 2010;35:1286-1293.

123. Martin C, Perrin G, Saux P, et al. Effects of norepinephrine on right ventricular function in septic shock patients. Intensive Care Med. 1994;20:444-447.

124. Eichinger MR, Walker BR. Enhanced pulmonary arterial dila-tion to arginine vasopressin in chronically hypoxic rats. Am J Physiol. 1994;267:H2413-H2419.

125. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest. 1993;103:1241-1245.

126. Leather HA, Ver Eycken K, Segers P, et al. Effects of levosi-mendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med. 2003;31:2339-2343.

127. Missant C, Rex S, Segers P, et al. Levosimendan improves right ventriculovascular coupling in a porcine model of right ven-tricular dysfunction. Crit Care Med. 2007;35:707-715.

128. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007;153:127-132.

129. Hoeper MM, Olschewski H, Ghofrani HA, et al. A compari-son of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol. 2000;35:176-182.

130. Walmrath D, Schneider T, Schermuly R, et al. Direct com-parison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:991-996.


References 5

131. Kooter AJ, Ijzerman RG, Kamp O, et al. No effect of epopros-tenol on right ventricular diameter in patients with acute pul-monary embolism: a randomized controlled trial. BMC Pulm Med. 2010;10:18.

132. Wang H, Gong M, Zhou B, et al. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther. 2009;26:462-468.

133. Ziegler JW, Ivy DD, Wiggins JW, et al. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:1388-1395.

134. Kinsella JP, Torielli F, Ziegler JW, et al. Dipyridamole augmenta-tion of response to nitric oxide. Lancet. 1995;346:647-648.

135. Wang L, Zhu du M, Su X, et al. Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs. Exp Lung Res. 2004;30:31-42.

136. Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J. 2004;25:431-436.

137. Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on hae-modynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008;21:824-832.

138. Preston IR, Klinger JR, Houtches J, et al. Acute and chronic effects of sildenafil in patients with pulmonary arterial hyper-tension. Respir Med. 2005;99:1501-1510.

139. Ghofrani HA WR, Rose F, et al. Sildenal for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895-900.

140. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999;91:307-310.

141. Bigatello LM, Hess D, Dennehy KC, et al. Sildenafil can increase the response to inhaled nitric oxide. Anesthesiology. 2000;92:1827-1829.

142. Schermuly RT, Leuchte H, Ghofrani HA, et al. Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003;22:342-347.

143. Namachivayam P, Theilen U, Butt WW, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006;174:1042-1047.

144. Siobal MS, Hess DR. Are inhaled vasodilators useful in acute lung injury and acute respiratory distress syndrome? Respir Care. 2010;55:144-157; discussion 157-161.

145. Afshari A, Brok J, Moller AM, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev. 2010:CD002787.

146. Adhikari NK, Burns KE, Friedrich JO, et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ. 2007;334:779.

147. Vachiery JL, Simonneau G. Management of severe pulmonary arterial hypertension. Eur Respir Rev. 2010;19:279-287.

148. Geiger R, Treml B, Kleinsasser A, et al. Intravenous tezosentan and vardenafil attenuate acute hypoxic pulmonary hyperten-sion. High Alt Med Biol. 2008;9:223-227.

149. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart

failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009-2019.

150. Amato MB, Barbas CS, Medeiros DM, et al. Beneficial effects of the “open lung approach” with low distending pressures in acute respiratory distress syndrome. A prospective randomized study on mechanical ventilation. Am J Respir Crit Care Med. 1995;152:1835-1846.

151. Puybasset L, Stewart T, Rouby JJ, et al. Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiology. 1994;80:1254-1267.

152. Mekontso Dessap A, Charron C, Devaquet J, et al. Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome. Intensive Care Med. 2009;35:1850-1858.

153. Jardin F, Brun-Ney D, Hardy A, et al. Combined thermodilution and two-dimensional echocardiographic evaluation of right ventricular function during respiratory support with PEEP. Chest. 1991;99:162-168.

154. Pinsky MR, Desmet JM, Vincent JL. Effect of positive end-expiratory pressure on right ventricular function in humans. Am Rev Respir Dis. 1992;146:681-687.

155. Fougeres E, Teboul JL, Richard C, et al. Hemodynamic impact of a positive end-expiratory pressure setting in acute respiratory distress syndrome: importance of the volume status. Crit Care Med. 2010;38:802-807.

156. van den Berg PC, Jansen JR, Pinsky MR. Effect of positive pressure on venous return in volume-loaded cardiac surgical patients. J Appl Physiol. 2002;92:1223-1231.

157. Pinsky MR. Determinants of pulmonary arterial flow variation during respiration. J Appl Physiol. 1984;56:1237-1245.

158. Bouferrache K, Vieillard-Baron A. Acute respiratory distress syndrome, mechanical ventilation, and right ventricular func-tion. Curr Opin Crit Care. 2011;17:30-35.

159. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.

160. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart fail-ure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.

161. Tang DG, Oyer PE, Mallidi HR. Ventricular assist devices: history, patient selection, and timing of therapy. J Cardiovasc Transl Res. 2009;2:159-167.

162. Craig ML. Management of right ventricular failure in the era of ventricular assist device therapy. Curr Heart Fail Rep. 2011;8: 65-71.

163. Chen JM, Levin HR, Rose EA, et al. Experience with right ven-tricular assist devices for perioperative right-sided circulatory failure. Ann Thorac Surg. 1996;61:305-310; discussion 303-311.

164. Reiss N, El-Banayosy A, Mirow N, et al. Implantation of the Biomedicus centrifugal pump in post-transplant right heart failure. J Cardiovasc Surg (Torino). 2000;41:691-694.

165. Drakos SG, Janicki L, Horne BD, et al. Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol. 2010;105:1030-1035.


References6

166. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al. Right ven-tricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg. 2002;73:745-750.

167. Prutkin JM, Strote JA, Stout KK. Percutaneous right ventricular assist device as support for cardiogenic shock due to right ven-tricular infarction. J Invasive Cardiol. 2008;20:E215-E216.

168. Lango R, Kowalik MM, Klajbor K, et al. Circulatory support with right ventricular assist device and intra-aortic balloon counter-pulsation in patient with right ventricle failure after pulmonary embolectomy. Interact Cardiovasc Thorac Surg. 2008;7:643-645.

169. Yano M, Onitsuka T, Shibata K, et al. Efficacy and safety of a percutaneous right ventricular assist system. Ann Thorac Surg. 1996;61:1231-1235.

170. Kapur NK, Paruchuri V, Korabathina R, et al. Effects of a per-cutaneous mechanical circulatory support device for medically refractory right ventricular failure. J Heart Lung Transplant. 2011;30:1360-1367.

171. Patel ND, Weiss ES, Schaffer J, et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. Ann Thorac Surg. 2008;86:832-840; discussion 832-840.

172. Strueber M, Hoeper MM, Fischer S, et al. Bridge to thoracic organ transplantation in patients with pulmonary arterial hyper-tension using a pumpless lung assist device. Am J Transplant. 2009;9:853-857.


Chapter 39

REFERENCES

1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. March 8, 1999;159(5):445-453.

2. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmo-nary embolism in the United States: evidence of overdiagnosis. Arch Intern Med. May 9, 2011;171(9):831-837.

3. Tapson VF. Acute pulmonary embolism: comment on “time trends in pulmonary embolism in the United States.” Arch Intern Med. May 9, 2011;171(9):837-839.

4. Ashrani AA, Heit JA. Caution on interpreting the time trends in pulmonary embolism as “overdiagnosis.” Arch Intern Med. November 28, 2011;171(21):1962.

5. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. January-February 1975;17(4):259-270.

6. Hermann RE, Davis JH, Holden WD. Pulmonary embolism. A clinical and pathologic study with emphasis on the effect of pro-phylactic therapy with anticoagulants. Am J Surg. July 1961;102: 19-28.

7. Byrne JJ. Phlebitis; a study of 748 cases at the Boston City Hospital. N Engl J Med. October 6, 1955;253(14):579-586.

8. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med. May 28, 2001;161(10):1268-1279.

9. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA. July 26, 1995;274(4):335-337.

10. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93(2):259-262.

11. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis. Chest. July 1998;114(1):207-213.

12. Munoz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest. January 2008;133(1):143-148.

13. Kommareddy A, Zaroukian MH, Hassouna HI. Upper extrem-ity deep venous thrombosis. Semin Thromb Hemost. February 2002;28(1):89-99.

14. Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Recurrent thrombosis and survival after a first venous throm-

bosis of the upper extremity. Circulation. September 23, 2008;118(13):1366-1372.

15. Chopin C, Fesard P, Mangalaboyi J, et al. Use of capnography in diagnosis of pulmonary embolism during acute respiratory failure of chronic obstructive pulmonary disease. Crit Care Med. April 1990;18(4):353-357.

16. Rodger MA, Jones G, Rasuli P, et al. Steady-state end-tidal alve-olar dead space fraction and D-dimer: bedside tests to exclude pulmonary embolism. Chest. July 2001;120(1):115-119.

17. Kline JA, Israel EG, Michelson EA, O'Neil BJ, Plewa MC, Portelli DC. Diagnostic accuracy of a bedside D-dimer assay and alveolar dead-space measurement for rapid exclusion of pulmonary embo-lism: a multicenter study. JAMA. February 14, 2001;285(6):761-768.

18. Kline JA, Hogg MM, Courtney DM, et al. D-dimer and exhaled CO2/O2 to detect segmental pulmonary embolism in moderate-risk patients. Am J Respir Crit Care Med. 2010;182(5):669-675.

19. Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med. October 2007;120(10):871-879.

20. D’Alonzo GE, Dantzker DR. Gas exchange alterations follow-ing pulmonary thromboembolism. Clin Chest Med. September 1984;5(3):411-419.

21. Stein PD, Goldhaber SZ, Henry JW, Miller AC. Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest. January 1996;109(1):78-81.

22. Manier G, Castaing Y, Guenard H. Determinants of hypoxemia during the acute phase of pulmonary embolism in humans. Am Rev Respir Dis. August 1985;132(2):332-338.

23. Santolicandro A, Prediletto R, Fornai E, et al. Mechanisms of hypoxemia and hypocapnia in pulmonary embolism. Am J Respir Crit Care Med. July 1995;152(1):336-347.

24. Elliott CG. Pulmonary physiology during pulmonary embo-lism. Chest. April 1992;101(suppl 4):163S-171S.

25. Tapson VF. Acute pulmonary embolism. N Engl J Med. March 6, 2008;358(10):1037-1052.

26. Belenkie I, Dani R, Smith ER, Tyberg JV. Ventricular interaction during experimental acute pulmonary embolism. Circulation. September 1988;78(3):761-768.

27. Belenkie I, Sas R, Mitchell J, Smith ER, Tyberg JV. Opening the pericardium during pulmonary artery constriction improves cardiac function. J Appl Physiol. March 1, 2004;96(3): 917-922.


References2

28. Stein PD, Willis PW III, DeMets DL. History and physical examination in acute pulmonary embolism in patients with-out preexisting cardiac or pulmonary disease. Am J Cardiol. February 1981;47(2):218-223.

29. Worsley DF, Alavi A, Aronchick JM, Chen JT, Greenspan RH, Ravin CE. Chest radiographic findings in patients with acute pulmonary embolism: observations from the PIOPED Study. Radiology. October 1, 1993;189(1):133-136.

30. Raghav KP, Makkuni P, Figueredo VM. A review of electro-cardiography in pulmonary embolism: recognizing pulmonary embolus masquerading as ST-elevation myocardial infarction. Rev Cardiovasc Med. 2011;12(3):157-163.

31. Cozzi PJ, Hall JB, Schmidt GA. Pulmonary artery diastolic-occlusion pressure gradient is increased in acute pulmonary embolism. Crit Care Med. September 1995;23(9):1481-1484.

32. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgi-cal patients. N Engl J Med. January 2, 2003;348(1):5-14.

33. Network NARDCT; Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 2006;354(21):2213-2224.

34. Patel JJ, Chandrasekaran K, Maniet AR, Ross JJ Jr, Weiss RL, Guidotti JA. Impact of the incidental diagnosis of clinically unsuspected central pulmonary artery thromboembolism in treatment of critically ill patients. Chest. April 1994;105(4): 986-990.

35. Bova C, Greco F, Misuraca G, et al. Diagnostic utility of echo-cardiography in patients with suspected pulmonary embolism. Am J Emerg Med. May 2003;21(3):180-183.

36. Miniati M, Monti S, Pratali L, et al. Value of transthoracic echo-cardiography in the diagnosis of pulmonary embolism: results of a prospective study in unselected patients. Am J Med. May 2001;110(7):528-535.

37. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. September 1997;134(3):479-487.

38. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dys-function. Circulation. June 20, 2000;101(24):2817-2822.

39. Wolfe MW, Lee RT, Feldstein ML, Parker JA, Come PC, Goldhaber SZ. Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism. Am Heart J. May 1994;127(5):1371-1375.

40. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: manage-ment of patients with suspected pulmonary embolism present-ing to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med. July 17, 2001;135(2): 98-107.

41. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous throm-boembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest. June 2008;133(suppl 6):454S-545S.

42. Stein PD, Fowler SE, Goodman LR, et al. Multidetector com-puted tomography for acute pulmonary embolism. N Engl J Med. June 1, 2006;354(22):2317-2327.

43. Russo V, Piva T, Lovato L, Fattori R, Gavelli G. Multidetector CT: a new gold standard in the diagnosis of pulmonary embo-lism? State of the art and diagnostic algorithms. Radiol Med. January-February 2005;109(1-2):49-61; quiz 43-62.

44. Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med. July 15, 2010;363(3):266-274.

45. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. February 1, 2000;132(3):227-232.

46. Mullins MD, Becker DM, Hagspiel KD, Philbrick JT. The role of spiral volumetric computed tomography in the diagnosis of pul-monary embolism. Arch Intern Med. February 14, 2000;160(3): 293-298.

47. PIOPED_investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA. May 23-30, 1990;263(20): 2753-2759.

48. Stein PD, Goodman LR, Hull RD, Dalen JE, Matta F. Diagnosis and management of isolated subsegmental pulmonary embo-lism: review and assessment of the options. Clin Appl Thromb Hemost. September 23, 2011; epub ahead of print.

49. Meaney JF, Weg JG, Chenevert TL, Stafford-Johnson D, Hamilton BH, Prince MR. Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med. May 15, 1997;336(20):1422-1427.

50. Oudkerk M, van Beek EJ, Wielopolski P, et al. Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a prospective study. Lancet. May 11, 2002;359(9318):1643-1647.

51. Stein PD, Chenevert TL, Fowler SE, et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med. April 6, 2010;152(7):434-443, W142-433.

52. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med. April 15, 1998;128(8):663-677.

53. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clin-ical assessment of deep-vein thrombosis. Lancet. May 27, 1995;345(8961):1326-1330.

54. Isma N, Svensson PJ, Gottsater A, Lindblad B. Upper extrem-ity deep venous thrombosis in the population-based Malmo thrombophilia study (MATS). Epidemiology, risk factors, recurrence risk, and mortality. Thromb Res. June 2010;125(6): e335-e338.

55. Di Nisio M, Van Sluis GL, Bossuyt PM, Buller HR, Porreca E, Rutjes AW. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost. April 2010;8(4):684-692.

56. Henry JW, Stein PD, Gottschalk A, Relyea B, Leeper KV Jr. Scintigraphic lung scans and clinical assessment in critically ill patients with suspected acute pulmonary embolism. Chest. February 1996;109(2):462-466.

57. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a system-atic review. Ann Intern Med. April 20, 2004;140(8):589-602.


References 3

58. Wells PS, Anderson DR, Ginsberg J. Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and noninvasive diagnostic tests. Semin Thromb Hemost. 2000;26(6):643-656.

59. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. September 2001;120(3):915-922.

60. Brathwaite CE, O’Malley KF, Ross SE, Pappas P, Alexander J, Spence RK. Continuous pulse oximetry and the diagnosis of pulmonary embolism in critically ill trauma patients. J Trauma. October 1992;33(4):528-530; discussion 521-530.

61. Stein PD, Athanasoulis C, Alavi A, et al. Complications and validity of pulmonary angiography in acute pulmonary embo-lism. Circulation. February 1992;85(2):462-468.

62. Henry JW, Relyea B, Stein PD. Continuing risk of thromboem-boli among patients with normal pulmonary angiograms. Chest. May 1995;107(5):1375-1378.

63. Forauer AR, McLean GK, Wallace LP. Clinical follow-up of patients after a negative digital subtraction pulmonary arterio-gram in the evaluation of pulmonary embolism. J Vasc Interv Radiol. November-December 1998;9(6):903-908.

64. van Rooij WJ, den Heeten GJ, Sluzewski M. Pulmonary embo-lism: diagnosis in 211 patients with use of selective pulmonary digital subtraction angiography with a flow-directed catheter. Radiology. June 1995;195(3):793-797.

65. Fred HL, Axelrad MA, Lewis JM, Alexander JK. Rapid resolu-tion of pulmonary thromboemboli in man. An angiographic study. JAMA. June 27, 1966;196(13):1137-1139.

66. Wittram C, Waltman AC, Shepard JA, Halpern E, Goodman LR. Discordance between CT and angiography in the PIOPED II study. Radiology. September 2007;244(3):883-889.

67. Mills SR, Jackson DC, Older RA, Heaston DK, Moore AV. The incidence, etiologies, and avoidance of complications of pulmonary angiography in a large series. Radiology. August 1980;136(2):295-299.

68. Perlmutt LM, Braun SD, Newman GE, Oke EJ, Dunnick NR. Pulmonary arteriography in the high-risk patient. Radiology. Jane 1987;162(1 pt 1):187-189.

69. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. October 2000;84(4): 548-552.

70. Jimenez D, Aujesky D, Moores L, et al. Simplification of the pul-monary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. August 9, 2010;170(15):1383-1389.

71. Aujesky D, Roy P-M, LeManach CdP, et al. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J. February 2006;27(4):476-481.

72. Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation. September 3, 2002;106(10):1263-1268.

73. Spirk D, Aujesky D, Husmann M, et al. Cardiac troponin test-ing and the simplified Pulmonary Embolism Severity Index. The SWIss Venous ThromboEmbolism Registry (SWIVTER). Thromb Haemost. November 3, 2011;106(5):978-984.

74. Lankeit M, JimÃ©nez D, Kostrubiec M, et al. Predictive value of the high-sensitivity troponin T assay and the simplified

pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism/clinical perspective. Circulation. December 13, 2011;124(24):2716-2724.

75. ten Wolde M, Tulevski II, Mulder JW, et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation. April 29, 2003;107(16): 2082-2084.

76. Sohne M, Ten Wolde M, Boomsma F, Reitsma JB, Douketis JD, Buller HR. Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism. J Thrombosis Haemostasis. 2006;4(3):552-556.

77. Riera-Mestre A, JimÉNez D, Muriel A, et al. Thrombolytic ther-apy and outcome of patients with an acute symptomatic pulmo-nary embolism. J Thrombosis Haemostasis. 2012;10(5):751-759.

78. Schellong SM, Schwarz T, Kropp J, Prescher Y, Beuthien-Baumann B, Daniel WG. Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism. Thromb Haemost. September 1999;82(suppl 1):127-129.

79. Aschwanden M, Labs KH, Engel H, et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. Thromb Haemost. January 2001;85(1): 42-46.

80. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. January 2001;119 (suppl 1):176S-193S.

81. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost. June 2002;28(suppl 2):15-24.

82. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. June 18, 1960;1(7138):1309-1312.

83. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med. February 15, 1992;116(4):279-284.

84. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembo-lism during heparin treatment for deep vein thrombosis. Arch Intern Med. December 8-22, 1997;157(22):2562-2568.

85. Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI. Early Anticoagulation Is Associated With Reduced Mortality for Acute Pulmonary Embolism. Chest. June 1, 2010;137(6):1382-1390.

86. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med. November 1, 1993;119(9):874-881.

87. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. May 3, 1990;322(18):1260-1264.

88. Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med. March 1984;76(3):393-397.

89. Mismetti P, Quenet S, Levine M, et al. Enoxaparin in the treat-ment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest. October 2005;128(4):2203-2210.


References4

90. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. April 1987;82(4):703-713.

91. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. February 2011;139(2): 271-278.

92. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. April 1993; 305(4):208-215.

93. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin. 2011;27(4):805-823.

94. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate plate-let-derived microparticles with procoagulant activity: an expla-nation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. December 1, 1994;84(11):3691-3699.

95. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with hep-arin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. June 1, 1994;83(11):3232-3239.

96. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. May 18, 1995;332(20):1330-1335.

97. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. November 1, 2006;108(9):2937-2941.

98. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. April 2006;4(4):759-765.

99. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Pulmonaire. N Engl J Med. September 4, 1997;337(10):663-669.

100. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta- analysis of randomized, controlled trials. Ann Intern Med. February 3, 2004;140(3):175-183.

101. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ. July 30, 1994;309(6950):299-304.

102. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight hep-arin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. July 10, 2003;349(2):146-153.

103. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary pre-vention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. August 12-26, 2002;162(15):1729-1735.

104. Walenga JM, Jeske WP, Prechel MM, Bacher P, Bakhos M. Decreased prevalence of heparin-induced thrombocytopenia

with low-molecular-weight heparin and related drugs. Semin Thromb Hemost. February 2004;30(suppl 1):69-80.

105. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replace-ment. N Engl J Med. November 6, 1997;337(19):1329-1335.

106. Crowther MA, Warkentin TE. Bleeding risk and the manage-ment of bleeding complications in patients undergoing antico-agulant therapy: focus on new anticoagulant agents. Blood. May 15, 2008;111(10):4871-4879.

107. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. September 1, 2006;108(5):1492-1496.

108. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. August 1, 2000;96(3):846-851.

109. Hacquard M, de Maistre E, Lecompte T. Lepirudin: is the approved dosing schedule too high? J Thromb Haemost. November 2005;3(11):2593-2596.

110. Jang IK, Brown DF, Giugliano RP, et al. A multicenter, random-ized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol. June 1999;33(7):1879-1885.

111. Harenberg J, Marx S, Krejczy M, Wehling M. New antico-agulants—promising and failed developments. Br J Pharmacol. 2012;165(2):363-372.

112. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. October 30, 2003;349(18):1695-1702.

113. Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297.

114. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by pro-thrombin complex concentrate/clinical perspective. Circulation. October 4, 2011;124(14):1573-1579.

115. Prandoni P. Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. Eur J Haematol. 2012;89(4):281-287.

116. Moser KM. Venous thromboembolism. Am Rev Respir Dis. January 1990;141(1):235-249.

117. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. February 12, 1998;338(7):409-415.

118. Streiff MB. Vena caval filters: a comprehensive review. Blood. June 15, 2000;95(12):3669-3677.

119. Asch MR. Initial experience in humans with a new retrievable inferior vena cava filter. Radiology. December 2002;225(3):835-844.

120. Millward SF, Bhargava A, Aquino J Jr, et al. Gunther Tulip filter: preliminary clinical experience with retrieval. J Vasc Interv Radiol. January 2000;11(1):75-82.


References 5

121. Bergqvist D. The role of vena caval interruption in patients with venous thromboembolism. Prog Cardiovasc Dis. July-August 1994;37(1):25-37.

122. Clagett GP, Anderson FA Jr, Geerts W, et al. Prevention of venous thromboembolism. Chest. November 1998;114(suppl 5):531S-560S.

123. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol. September 1992;20(3): 520-526.

124. Witty LA, Krichman A, Tapson VF. Thrombolytic therapy for venous thromboembolism. Utilization by practicing pulmon-ologists. Arch Intern Med. July 25, 1994;154(14):1601-1604.

125. Diehl JL, Meyer G, Igual J, et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol. December 1, 1992;70(18):1477-1480.

126. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assess-ing right-ventricular function and pulmonary perfusion. Lancet. February 27, 1993;341(8844):507-511.

127. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2(3):227-229.

128. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med. October 10, 2002;347(15):1131-1132.

129. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest. June 1999;115(6):1695-1707.

130. Hamel E, Pacouret G, Vincentelli D, et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest. July 2001;120(1):120-125.

131. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. October 10, 2002;347(15):1143-1150.

132. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embo-lism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. April 24, 1999;353(9162):1386-1389.

133. Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmo-nary embolism. Chest. April 2004;125(4):1539-1545.

134. Meyer G, Vicaut E, Thierry D. Fibrinolysis for Patients with Intermediate Risk Pulmonary Embolism. NEJM. 2014;370(15): 1402-1411.

135. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemo-dynamic outcome and one-year follow-up. J Am Coll Cardiol. April 1998;31(5):1057-1063.

136. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J. July 1997;18(7):1141-1148.

137. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute

massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol. February 1992;19(2):239-245.

138. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A random-ized controlled multicenter trial. Chest. September 1994;106(3): 712-717.

139. Goldhaber SZ, Feldstein ML, Sors H. Two trials of reduced bolus alteplase in the treatment of pulmonary embolism. An overview. Chest. September 1994;106(3):725-726.

140. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter random-ized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest. September 1994;106(3):718-724.

141. Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activa-tor in the treatment of acute massive pulmonary embolism. Circulation. February 1988;77(2):353-360.

142. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of uro-kinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. July 1992;20(1):24-30.

143. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embo-lism. Consideration of noninvasive management. Ann Intern Med. September 1, 1994;121(5):313-317.

144. Molina JE, Hunter DW, Yedlicka JW, Cerra FB. Thrombolytic therapy for postoperative pulmonary embolism. Am J Surg. April 1992;163(4):375-380; discussion 371-380.

145. Girard P, Baldeyrou P, Le Guillou JL, Lamer C, Grunenwald D. Thrombolysis for life-threatening pulmonary embolism 2 days after lung resection. Am Rev Respir Dis. June 1993;147(6 pt 1):1595-1597.

146. Severi P, Lo Pinto G, Poggio R, Andrioli G. Urokinase thrombo-lytic therapy of pulmonary embolism in neurosurgically treated patients. Surg Neurol. December 1994;42(6):469-470.

147. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med. December 15, 1989;111(12):1010-1022.

148. Belenkie I, Dani R, Smith ER, Tyberg JV. Effects of volume loading during experimental acute pulmonary embolism. Circulation. July 1989;80(1):178-188.

149. Jardin F, Genevray B, Brun-Ney D, Margairaz A. Dobutamine: a hemodynamic evaluation in pulmonary embolism shock. Crit Care Med. December 1985;13(12):1009-1012.

150. Molloy WD, Lee KY, Girling L, Schick U, Prewitt RM. Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis. November 1984;130(5):870-874.

151. Boulain T, Lanotte R, Legras A, Perrotin D. Efficacy of epi-nephrine therapy in shock complicating pulmonary embolism. Chest. July 1993;104(1):300-302.

152. Estagnasie P, Le Bourdelles G, Mier L, Coste F, Dreyfuss D. Use of inhaled nitric oxide to reverse flow through a patent foramen ovale during pulmonary embolism. Ann Intern Med. May 1, 1994;120(9):757-759.


References6

153. Lund O, Nielsen TT, Schifter S, Roenne K. Treatment of pul-monary embolism with full-dose heparin, streptokinase or embolectomy—results and indications. Thorac Cardiovasc Surg. August 1986;34(4):240-246.

154. Gulba DC, Schmid C, Borst HG, Lichtlen P, Dietz R, Luft FC. Medical compared with surgical treatment for massive pulmo-nary embolism. Lancet. March 5, 1994;343(8897):576-577.

155. Gray HH, Miller GA, Paneth M. Pulmonary embolectomy: its place in the management of pulmonary embolism. Lancet. June 25, 1988;1(8600):1441-1445.

156. Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmo-nary embolectomy for treatment of major pulmonary embolism. Ann Thorac Surg. March 2004;77(3):819-823; discussion 823.

157. Alpert JS, Smith RE, Ockene IS, Askenazi J, Dexter L, Dalen JE. Treatment of massive pulmonary embolism: the role of pulmo-nary embolectomy. Am Heart J. April 1975;89(4):413-418.

158. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. May 27, 2004;350(22):2257-2264.

159. Timsit JF, Reynaud P, Meyer G, Sors H. Pulmonary embolec-tomy by catheter device in massive pulmonary embolism. Chest. September 1991;100(3):655-658.

160. Schmitz-Rode T, Janssens U, Schild HH, Basche S, Hanrath P, Gunther RW. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. Chest. November 1998;114(5): 1427-1436.

161. Haskal ZJ, Soulen MC, Huettl EA, Palevsky HI, Cope C. Life-threatening pulmonary emboli and cor pulmonale: treat-ment with percutaneous pulmonary artery stent placement. Radiology. May 1994;191(2):473-475.

162. Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmo-nary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009;20(11):1431-1440.

163. Kuo WT, Hofmann LV. Drs. Kuo and Hofmann respond. J Vasc Interv Radiol. 2009;21(11):1776-1777.

164. Toglia MR, Weg JG. Venous thromboembolism during preg-nancy. N Engl J Med. July 11, 1996;335(2):108-114.

165. Kaunitz AM, Hughes JM, Grimes DA, Smith JC, Rochat RW, Kafrissen ME. Causes of maternal mortality in the United States. Obstet Gynecol. May 1985;65(5):605-612.

166. Ponto JA. Fetal dosimetry from pulmonary imaging in pregnancy. Revised estimates. Clin Nucl Med. February 1986;11(2):108-109.

167. Didolkar SM, Koontz C, Schimberg PI. Phleborheography in pregnancy. Obstet Gynecol. March 1983;61(3):363-366.

168. Ginsberg JS, Bates SM. Management of venous thromboem-bolism during pregnancy. J Thromb Haemost. July 2003;1(7): 1435-1442.

169. Ginsberg JS, Hirsh J. Use of anticoagulants during pregnancy. Chest. February 1989;95(suppl 2):156S-160S.

170. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. April 1993;168(4):1265-1270.

171. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol. May 1994;170(5 pt 1):1315-1320.

172. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod. May 2004;19(5):1211-1214.

173. Lesser BA, Leeper KV, Jr., Stein PD, et al. The diagnosis of acute pulmonary embolism in patients with chronic obstructive pul-monary disease. Chest. July 1992;102(1):17-22.

174. Lippmann M, Fein A. Pulmonary embolism in the patient with chronic obstructive pulmonary disease. A diagnostic dilemma. Chest. January 1981;79(1):39-42.

175. Prescott SM, Richards KL, Tikoff G, Armstrong JD, Jr., Shigeoka JW. Venous thromboembolism in decompensated chronic obstructive pulmonary disease. A prospective study. Am Rev Respir Dis. January 1981;123(1):32-36.

176. Phillips B, Woodring J. Autoanticoagulation does not preclude pulmonary emboli. Lung. 1987;165(1):37-43.

177. Needleman SW, Stein MN, Hoak JC. Pulmonary embolism in patients with acute leukemia and severe thrombocytopenia. West J Med. July 1981;135(1):9-13.

178. Cade JF. High risk of the critically ill for venous thromboembo-lism. Crit Care Med. July 1982;10(7):448-450.

179. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. Chest. June 1, 2008;133(suppl 6):381S-453S.

180. PROTECT_investigators. Dalteparin versus unfractionated hepa-rin in critically ill patients. N Engl J Med. 2011;364(14):1305-1314.

181. McLeod AG, Geerts W. Venous thromboembolism prophylaxis in critically ill patients. Crit Care Clin. October 2011;27(4): 765-780, v.

182. Morris WP, Butler BD, Tonnesen AS, Allen SJ. Continuous venous air embolism in patients receiving positive end- expiratory pressure. Am Rev Respir Dis. April 1993;147(4):1034-1037.

183. Tanus-Santos JE, Gordo WM, Udelsmann A, Cittadino MH, Moreno H Jr. Nonselective endothelin-receptor antagonism attenuates hemodynamic changes after massive pulmonary air embolism in dogs. Chest. July 2000;118(1):175-179.

184. Kapoor T, Gutierrez G. Air embolism as a cause of the systemic inflammatory response syndrome: a case report. Crit Care. October 2003;7(5):R98-R100.

185. Albertine KH. Lung injury and neutrophil density during air embolization in sheep after leukocyte depletion with nitrogen mustard. Am Rev Respir Dis. December 1988;138(6):1444-1453.

186. Sloan TB, Kimovec MA. Detection of venous air embo-lism by airway pressure monitoring. Anesthesiology. May 1986;64(5):645-647.

187. Butler BD, Hills BA. Transpulmonary passage of venous air emboli. J Appl Physiol. August 1985;59(2):543-547.

188. Marini JJ, Culver BH. Systemic gas embolism complicating mechanical ventilation in the adult respiratory distress syn-drome. Ann Intern Med. May 1, 1989;110(9):699-703.

189. Dutka AJ, Kochanek PM, Hallenbeck JM. Influence of granulo-cytopenia on canine cerebral ischemia induced by air embolism. Stroke. March 1989;20(3):390-395.

190. Roberts S, Johnson M, Davies S. Near-fatal air embolism: fibrin sheath as the portal of air entry. South Med J. October 2003;96(10):1036-1038.

191. Orebaugh SL. Venous air embolism: clinical and experimental considerations. Crit Care Med. August 1992;20(8):1169-1177.


References 7

192. Jorens PG, Van Marck E, Snoeckx A, Parizel PM. Nonthrombotic pulmonary embolism. Eur Respir J. August 2009;34(2):452-474.

193. Karuparthy VR, Downing JW, Husain FJ, et al. Incidence of venous air embolism during cesarean section is unchanged by the use of a 5 to 10 degree head-up tilt. Anesth Analg. November 1989;69(5):620-623.

194. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. June 15, 2006;354(24):2564-2575.

195. Jerome EH, Bonsignore MR, Albertine KH, et al. Timing of corticosteroid treatment. Effect of lung lymph dynamics in air injury in awake sheep. Am Rev Respir Dis. October 1990;142(4): 872-879.

196. Bessereau J, Genotelle N, Chabbaut C, et al. Long-term out-come of iatrogenic gas embolism. Intensive Care Medicine. 2010;36(7):1180-1187.

197. Godeau B, Schaeffer A, Bachir D, et al. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med. May 1996;153(5):1691-1696.

198. Schmid A, Tzur A, Leshko L, Krieger BP. Silicone embolism syndrome: a case report, review of the literature, and com-parison with fat embolism syndrome. Chest. June 2005;127(6): 2276-2281.

199. Fabian TC, Hoots AV, Stanford DS, Patterson CR, Mangiante EC. Fat embolism syndrome: prospective evaluation in 92 fracture patients. Crit Care Med. January 1990;18(1):42-46.

200. Hulman G. Pathogenesis of non-traumatic fat embolism. Lancet. June 18, 1988;1(8599):1366-1367.

201. Christie J, Robinson CM, Pell AC, McBirnie J, Burnett R. Transcardiac echocardiography during invasive intramedullary procedures. J Bone Joint Surg Br. May 1995;77(3):450-455.

202. Pell AC, Hughes D, Keating J, Christie J, Busuttil A, Sutherland GR. Brief report: fulminating fat embolism syndrome caused by paradoxical embolism through a patent foramen ovale. N Engl J Med. September 23, 1993;329(13):926-929.

203. Byrick RJ, Mullen JB, Mazer CD, Guest CB. Transpulmonary systemic fat embolism. Studies in mongrel dogs after cemented arthroplasty. Am J Respir Crit Care Med. November 1994;150(5 pt 1):1416-1422.

204. Vedrinne JM, Guillaume C, Gagnieu MC, Gratadour P, Fleuret C, Motin J. Bronchoalveolar lavage in trauma patients for diagno-sis of fat embolism syndrome. Chest. November 1992;102(5): 1323-1327.

205. Gitin TA, Seidel T, Cera PJ, Glidewell OJ, Smith JL. Pulmonary microvascular fat: the significance? Crit Care Med. May 1993;21(5):673-677.

206. Bone LB, Johnson KD, Weigelt J, Scheinberg R. Early versus delayed stabilization of femoral fractures. A prospective ran-domized study. J Bone Joint Surg Am. March 1989;71(3):336-340.

207. Johnson KD, Cadambi A, Seibert GB. Incidence of adult respira-tory distress syndrome in patients with multiple musculoskel-etal injuries: effect of early operative stabilization of fractures. J Trauma. May 1985;25(5):375-384.

208. Behrman SW, Fabian TC, Kudsk KA, Taylor JC. Improved out-come with femur fractures: early vs. delayed fixation. J Trauma. July 1990;30(7):792-797; discussion 797-798.

209. Pitto RP, Hamer H, Fabiani R, Radespiel-Troeger M, Koessler M. Prophylaxis against fat and bone-marrow embolism during total hip arthroplasty reduces the incidence of postoperative deep-vein thrombosis: a controlled, randomized clinical trial. J Bone Joint Surg Am. January 2002;84-A(1):39-48.

210. Kallenbach J, Lewis M, Zaltzman M, Feldman C, Orford A, Zwi S. “Low-dose” corticosteroid prophylaxis against fat embolism. J Trauma. October 1987;27(10):1173-1176.

211. Lindeque BG, Schoeman HS, Dommisse GF, Boeyens MC, Vlok AL. Fat embolism and the fat embolism syndrome. A double-blind therapeutic study. J Bone Joint Surg Br. January 1987;69(1): 128-131.

212. Schonfeld SA, Ploysongsang Y, DiLisio R, et al. Fat embolism prophylaxis with corticosteroids. A prospective study in high-risk patients. Ann Intern Med. October 1983;99(4):438-443.

213. Kubota T, Ebina T, Tonosaki M, Ishihara H, Matsuki A. Rapid improvement of respiratory symptoms associated with fat embolism by high-dose methylpredonisolone: a case report. J Anesth. 2003;17(3):186-189.


Chapter 40

REFERENCES

1. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the Colchicine for acute Pericarditis (COPE) trial. Circulation. 2005;112:2012-2016.

2. Lotrionte M, Biondi-Zoccai G, Imazio M, et al. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recur-rences. Am Heart J. 2010;160(4):662-670.

3. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (Colchicine for REcurrent pericarditis) Trial. Arch Intern Med. 2005;165:1987-1991.

4. Spodick DH. Acute cardiac tamponade. N Eng J Med. 2003;349:684-690.

5. Shabetai R. The pathophysiology of cardiac tamponade. Cardiovasc Clin. 1976;7(3):67-89.

6. Antman EM, Cargill V, Grossman W. Low-pressure cardiac tamponade. Ann Intern Med. 1979;91(3):403-406.

7. Armstrong WF, Schilt BF, Helper DJ, Dillon JC, Feigenbaum H. Diastolic collapse of the right ventricle with cardiac tampon-ade: an echocardiographic study. Circulation. June 1982;65(7): 1491-1496.

8. Burstow DJ, Oh JK, Bailey KR, Seward JB, Tajik AJ. Cardiac tamponade: characteristic Doppler observations. Mayo Clin Proc. 1989;64:312-324.

9. Tsang TS, Freeman WK, Sinak LJ, Seward JB. Echocardiographically guided pericardiocentesis: evolution and state-of- the-art technique. Mayo Clin Proc. 1998;73(7):647.

10. Isselbacher EM, Cigarroa JE, Eagle KA. Cardiac tamponade complicating proximal aortic dissection. Is pericardiocentesis harmful? Circulation. November 1994;90(5):2375-2378.

11. Ha JW, Oh JK, Ling LH, Nishimura RA, Seward JB, Tajik AJ. Annulus paradoxus: transmitral flow velocity to mitral annular velocity ratio is inversely proportional to pulmonary capillary

wedge pressure in patients with constrictive pericarditis. Circulation. 2001;104:976-978.

12. Santamore WP, Bartlett R, Van Buren SJ, Dowd MK, Kutcher MA. Ventricular coupling in constrictive pericarditis. Circulation. 1986;74:597-602.

13. Hurrell DG, Nishimura RA, Higano ST, et al. Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Circulation. 1996;93: 2007-2013.

14. Talreja DR, Nishimura RA, Oh JK, Holmes DR. Constrictive pericarditis in the modern era: novel criteria for diagnosis in the cardiac catheterization laboratory. J Am Coll Cardiol. 2008;51:315-319.

15. Ha JW, Oh JK, Schaff HV, et al. Impact of left ventricular func-tion on immediate and long-term outcomes after pericardi-ectomy in constrictive pericarditis. J Thorac Cardiovasc Surg. 2008;136(5):1136.

16. Chowdhury UK, Subramaniam GK, Kumar AS, et al. Pericardiectomy for constrictive pericarditis: a clinical, echo-cardiographic, and hemodynamic evaluation of two surgical techniques. Ann Thorac Surg. 2006:81(2):522.

17. Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive peri-carditis: etiology and cause-specific survival after pericardiec-tomy. J Am Coll Cardiol. 2004;43(8):1445.

18. Cameron J, Oesterle SN, Baldwin JC, Hancock EW. The etiologic spectrum of constrictive pericarditis. Am Heart J. 1987;113:354-360.

19. Haley JH, Tajik AJ, Danielson GK, Schaff HV, Mulvagh SL, Oh JK. Transient constrictive pericarditis: causes and natural history. J Am Coll Cardiol. 2004;43(2):271-275.

20. Sagrista-Sauleda J, Angel J, Sanchez A, Permanyer-Miralda G, Soler-Soler J. Effusive-constrictive pericarditis. N Engl J Med. 2004;350:469-475.


Chapter 41

REFERENCES

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;16;368(9540):1005-1011.

2. Iung B, Baron G, Tornos P, et al. Valvular heart disease in the community: a European experience. Curr Probl Cardiol. 2007;32:609-661.

3. Selzer A. Changing aspects of the natural history of valvular aortic stenosis. N Engl J Med. 1987;317:92.

4. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol. 1970;26:72.

5. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Circulation. 2008;118(15):e523-e661.

6. Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and cen-tral circulatory shunts. Am Heart J. 1951;41:1.

7. Malouf J, Le Tourneau T, Pellikka P, et al. Aortic valve stenosis in community medical practice: determinants of outcome and implications for aortic valve replacement. J Thorac Cardiovasc Surg. 2012;144(6):1421-1427.

8. Connolly HM, Oh JK, Schaff HV, et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction:result of aortic valve replacement in 52 patients. Circulation. 2000;101(16):1940-1946.

9. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation. June 5, 2007;115(22):2856-2864. Epub 2007 May 28.

10. Torsher LC, Shub C, Rettke SR, Brown DL. Risk of patients with severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol. February 15, 1998;81(4):448-452.

11. Carabello BA. Clinical practice. Aortic stenosis. N Engl J Med. February 28, 2002 ;346(9):677-682.

12. Nishimura RA, Grantham JA, Connolly HM, Schaff HV, Higano ST, Holmes DR Jr. Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the

clinical utility of the dobutamine challenge in the catheteriza-tion laboratory. Circulation. 2002;106(7):809-813.

13. Laissy JP, Messika-Zeitoun D, Serfaty JM, et al. Comprehensive evaluation of preoperative patients with aortic valve stenosis: usefulness of cardiac multidetector computed tomography. Heart. 2007;93(9):1121-1125.

14. Messika-Zeitoun D, Serfaty JM, Brochet E, et al. Multimodal assessment of the aortic annulus diameter: implications for transcatheter aortic valve implantation. J Am Coll Cardiol. January 19, 2010;55(3):186-194.

15. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297:845.

16. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348:1756-1763.

17. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. October 21, 2010;363(17):1597-1607.

18. Hara H, Pedersen WR, Ladich E, et al. Percutaneous bal-loon aortic valvuloplasty revisited: time for a renaissance? Circulation. 2007;115(12):e334

19. Moreno PR, Jang I-K, Newell JB, et al. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol. 1994;23:1071.

20. Roth RB, Palacios IF, Block PC. Percutaneous aortic balloon valvuloplasty: its role in the management of patients with aortic stenosis requiring major noncardiac surgery. J Am Coll Cardiol. 1989;13:1039.

21. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recom-mendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiog-raphy. J Am Soc Echocardiography. 2003;16(7):777-802.

22. Nienaber CA, von Kodolitsch Y, Nicolas V, et al. The diagnosis of thoracic aortic dissection by noninvasive imaging proce-dures. N Engl J Med. 1993;328:1.

23. Mann T, McLaurin L, Grossman W, et al. Assessing the hemo-dynamic severity of acute aortic regurgitation due to infective endocarditis. N Engl J Med. 1975;293:108.

24. Aranki SF, Santini F, Adams DH, et al. Aortic valve endocarditis. Determinants of early survival and late morbidity. Circulation. 1994;90(pt 2):II-175.


References2

25. Miller RR, Vismara LA, DeMaria AN, et al. Afterload reduc-tion therapy with nitroprusside in severe aortic regurgitation: improved cardiac performance and reduced regurgitant vol-ume. Am J Cardiol. 1976;38:564.

26. Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla VS. Nifedipine in asymptomatic patients with severe aortic regur-gitation and normal left ventricular function. N Engl J Med. 1994;331:689-694.

27. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med. 2005;353:1342-1349.

28. Nishimura RA, Rihal CS, Tajik AJ, Holmes DR Jr. Accurate measurement of the transmitral gradient in patients with mitral stenosis: a simultaneous catheterization and Doppler echocar-diographic study. J Am Coll Cardiol. July 1994;24(1):152-158.

29. Nishimura RA, Holmes DR Jr, Reeder GS. Efficacy of percu-taneous mitral balloon valvuloplasty with the inoue balloon. Mayo Clin Proc. March 1991;66(3):276-282.

30. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgita-tion. Lancet. April 18, 2009;373(9672):1382-1394.

31. Yiu SF, Enriquez-Sarano M, Tribouilloy C, Seward JB, Tajik AJ. Determinants of the degree of functional mitral regurgitation in patients with systolic left ventricular dysfunction: a quanti-tative clinical study. Circulation. September 19, 2000;102(12): 1400-1406.

32. Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical out-come of mitral regurgitation due to flail leaflet. N Engl J Med. November 7, 1996;335(19):1417-1423.

33. Ross J. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. J Am Coll Cardiol. 1985;5:811.

34. Zile MR. Chronic aortic and mitral regurgitation. Choosing the optimal time for surgical correction. Cardiology Clin. 1991;9:239.

35. van Son JA, Danielson GK, Schaff HV, Miller FA Jr. Traumatic tricuspid valve insufficiency. Experience in thirteen patients. J Thorac Cardiovasc Surg. November 1994;108(5):893-898.

36. Messica-Zeitoun D, Thomson H, Bellamy M, et al. Medical and surgical outcome of tricuspid regurgitation caused by flail leaf-lets. J Thorac Cardiovasc Surg. 2004;128:296-302.

37. Cipriano PR, Billingham ME, Oyer PE, et al. Calcification of porcine prosthetic heart valves: a radiographic and light micro-scopic study. Circulation. 1982;66:1100.

38. Sugimoto JT, Karp RB. Homografts and cryopreserved valves. In: Crawford FA, ed. Cardiac Surgery: Current Heart Valve Prostheses. Vol 1. Philadelphia, PA: Hanley & Belfus; 1987:295.

39. O’Gara PT, Haldar SM. Infective endocarditis. In: Fuster V, Walsh RA, Harrington RA, eds. Hurst’s The Heart. 13th ed. New York: McGraw-Hill; 2011:chap 86.

40. Ivert TSA, Dismukes WE, Cobbs CG, et al. Prosthetic valve endocarditis. Circulation. 1984;69:223.

41. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. October 9, 2007;116(15):1736-1754.


Chapter 42

REFERENCES

1. Sorensen HR, Olsen H. Ruptured and dissecting aneurysms of the aorta. Incidence and prospects of surgery. Acta Chir Scand. 1964;128:644-650.

2. Wheat MW Jr. Acute dissection of the aorta. Cardiovasc Clin. 1987;17(3):241-262.

3. Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection: perspectives from the international registry of acute aortic dissection (IRAD). Eur J Vasc Endovasc Surg. 2009;37(2): 149-159.

4. Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and management: Part I: from etiology to diagnostic strategies. Circulation. 2003;108(5):628-635.

5. Larson EW, Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 cases. Am J Cardiol. 1984;53(6):849-855.

6. Fedak PW, de Sa MP, Verma S, et al. Vascular matrix remod-eling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg. 2003;126(3):797-806.

7. DeSanctis RW, Doroghazi RM, Austen WG, Buckley MJ. Aortic dissection. N Engl J Med. 1987;317(17):1060-1067.

8. Golledge J, Eagle KA. Acute aortic dissection. Lancet. 2008;372(9632):55-66.

9. Reece T, Green G, Kron I. Cardiac surgery in the adult. In: Cohn L, ed. Aortic dissection. New York: McGraw-Hill; 2008:1195-1222.

10. Onitsuka S, Akashi H, Tayama K, et al. Long-term outcome and prognostic predictors of medically treated acute type B aortic dissections. Ann Thorac Surg. 2004;78(4):1268-1273.

11. Eggebrecht H, Baumgart D, Herold U, et al. Interventional man-agement of aortic dissection. Herz. 2002;27(6):539-547.

12. Greenberg RK, Haulon S, Khwaja J, Fulton G, Ouriel K. Contemporary management of acute aortic dissection. J Endovasc Ther. 2003;10(3):476-485.

13. Shimono T, Kato N, Yasuda F, et al. Transluminal stent-graft placements for the treatments of acute onset and chronic aortic dissections. Circulation. 2002;106(12 suppl 1):I241-I247.

14. Shimizu H, Yoshino H, Udagawa H, et al. Prognosis of aortic intramural hemorrhage compared with classic aortic dissection. Am J Cardiol. 2000;85(6):792-795, A10.

15. Kitai T, Kaji S, Yamamuro A, et al. Clinical outcomes of medi-cal therapy and timely operation in initially diagnosed type a aortic intramural hematoma: a 20-year experience. Circulation. 2009;120(11 suppl):S292-S298.

16. Song JK, Yim JH, Ahn JM, et al. Outcomes of patients with acute type a aortic intramural hematoma. Circulation. 2009;120(21):2046-2052.

17. Estrera A, Miller C III, Lee TY, et al. Acute type A intra-mural hematoma: analysis of current management strategy. Circulation. 2009;120(11 suppl):S287-S291.

18. Sueyoshi E, Matsuoka Y, Sakamoto I, Uetani M, Hayashi K, Narimatsu M. Fate of intramural hematoma of the aorta: CT evaluation. J Comput Assist Tomogr. 1997;21(6):931-938.

19. Kang DH, Song JK, Song MG, et al. Clinical and echocardio-graphic outcomes of aortic intramural hemorrhage compared with acute aortic dissection. Am J Cardiol. 1998;81(2):202-206.

20. Nishigami K, Tsuchiya T, Shono H, Horibata Y, Honda T. Disappearance of aortic intramural hematoma and its sig-nificance to the prognosis. Circulation. 2000;102(19 suppl 3): III243-III247.

21. Evangelista A, Mukherjee D, Mehta RH, et al. Acute intramural hematoma of the aorta: a mystery in evolution. Circulation. 2005;111(8):1063-1070.

22. Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. Eur Heart J. 2001;22(18):1642-1681.

23. Sundt TM. Intramural hematoma and penetrating aortic ulcer. Curr Opin Cardiol. 2007;22(6):504-509.

24. Anagnostopoulos CE, Prabhakar MJ, Kittle CF. Aortic dissections and dissecting aneurysms. Am J Cardiol. 1972;30(3):263-273.

25. Rosman HS, Patel S, Borzak S, Paone G, Retter K. Quality of history taking in patients with aortic dissection. Chest. 1998;114(3):793-795.

26. Tsai TT, Bossone E, Isselbacher EM, et al. Clinical characteris-tics of hypotension in patients with acute aortic dissection. Am J Cardiol. 2005;95(1):48-52.

27. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic dis-ease: a report of the american college of cardiology foundation/american heart association task force on practice guidelines, american association for thoracic surgery, american college of radiology, american stroke association, society of cardiovas-cular anesthesiologists, society for cardiovascular angiography and interventions, society of interventional radiology, soci-ety of thoracic surgeons, and society for vascular medicine. Circulation. 2010;121(13):e266-e369.


References2

28. Gilon D, Mehta RH, Oh JK, et al. Characteristics and in-hospital outcomes of patients with cardiac tamponade complicating type A acute aortic dissection. Am J Cardiol. 2009;103(7):1029-1031.

29. Cambria RP, Brewster DC, Gertler J, et al. Vascular complica-tions associated with spontaneous aortic dissection. J Vasc Surg. 1988;7(2):199-209.

30. Hirst AE Jr, Johns VJ Jr, Kime SW Jr. Dissecting aneurysm of the aorta: a review of 505 cases. Medicine (Baltimore). 1958;37(3):217-279.

31. Heinemann MK, Buehner B, Schaefers HJ, Jurmann MJ, Laas J, Borst HG. Malperfusion of the thoracoabdominal vasculature in aortic dissection. J Card Surg. 1994;9(6):748-55; discussion 755-757.

32. Thorsen MK, San Dretto MA, Lawson TL, Foley WD, Smith DF, Berland LL. Dissecting aortic aneurysms: accuracy of computed tomographic diagnosis. Radiology. 1983;148(3):773-777.

33. Sommer T, Fehske W, Holzknecht N, et al. Aortic dissection: a comparative study of diagnosis with spiral CT, multiplanar transesophageal echocardiography, and MR imaging. Radiology. 1996;199(2):347-352.

34. Erbel R, Engberding R, Daniel W, Roelandt J, Visser C, Rennollet H. Echocardiography in diagnosis of aortic dissec-tion. Lancet. 1989;1(8636):457-461.

35. Bansal RC, Chandrasekaran K, Ayala K, Smith DC. Frequency and explanation of false negative diagnosis of aortic dissection by aortography and transesophageal echocardiography. J Am Coll Cardiol. 1995;25(6):1393-1401.

36. Nienaber CA, von Kodolitsch Y, Nicolas V, et al. The diagnosis of thoracic aortic dissection by noninvasive imaging proce-dures. N Engl J Med. 1993;328(1):1-9.

37. Wechsler RJ, Kotler MN, Steiner RM. Multimodality approach to thoracic aortic dissection. Cardiovasc Clin. 1986;17(1): 385-408.

38. Hagan PG, Nienaber CA, Isselbacher EM, et al. The interna-tional registry of acute aortic dissection (IRAD): new insights into an old disease. JAMA. 2000;283(7):897-903.

39. Schertler T, Glucker T, Wildermuth S, Jungius KP, Marincek B, Boehm T. Comparison of retrospectively ECG-gated and nongated MDCT of the chest in an emergency setting regarding workflow, image quality, and diagnostic certainty. Emerg Radiol. 2005;12(1-2):19-29.

40. Hayter RG, Rhea JT, Small A, Tafazoli FS, Novelline RA. Suspected aortic dissection and other aortic disorders: multi-detector row CT in 373 cases in the emergency setting. Radiology. 2006;238(3):841-852.

41. Khandheria BK, Tajik AJ, Taylor CL, et al. Aortic dissec-tion: review of value and limitations of two-dimensional echocardiography in a six-year experience. J Am Soc Echocardiogr. 1989;2(1):17-24.

42. Evangelista A, Avegliano G, Aguilar R, et al. Impact of contrast-enhanced echocardiography on the diagnostic algorithm of acute aortic dissection. Eur Heart J. 2010;31(4):472-479.

43. Cecconi M, Chirillo F, Costantini C, et al. The role of transtho-racic echocardiography in the diagnosis and management of acute type A aortic syndrome. Am Heart J. 2012;163(1):112-118.

44. Evangelista A, Garcia-del-Castillo H, Gonzalez-Alujas T, et al. Diagnosis of ascending aortic dissection by transesophageal echocardiography: utility of M-mode in recognizing artifacts. J Am Coll Cardiol. 1996;27(1):102-107.

45. Keren A, Kim CB, Hu BS, et al. Accuracy of biplane and multi-plane transesophageal echocardiography in diagnosis of typical acute aortic dissection and intramural hematoma. J Am Coll Cardiol. 1996;28(3):627-636.

46. Erbel R, Oelert H, Meyer J, et al. Effect of medical and surgical therapy on aortic dissection evaluated by transesophageal echo-cardiography. Implications for prognosis and therapy. The euro-pean cooperative study group on echocardiography. Circulation. 1993;87(5):1604-1615.

47. Chirillo F, Cavallini C, Longhini C, et al. Comparative diagnos-tic value of transesophageal echocardiography and retrograde aortography in the evaluation of thoracic aortic dissection. Am J Cardiol. 1994;74(6):590-595.

48. Agricola E, Slavich M, Bertoglio L, et al. The role of contrast enhanced transesophageal echocardiography in the diagnosis and in the morphological and functional characterization of acute aortic syndromes. Int J Cardiovasc Imaging. 2014;30(1):31-38.

49. Pearson AC, Castello R, Labovitz AJ. Safety and utility of trans-esophageal echocardiography in the critically ill patient. Am Heart J. 1990;119(5):1083-1089.

50. Silverman JM, Raissi S, Tyszka JM, Trento A, Herfkens RJ. Phase-contrast cine MR angiography detection of thoracic aortic dissection. Int J Card Imaging. 2000;16(6):461-470.

51. Hartnell GG. Imaging of aortic aneurysms and dissection: CT and MRI. J Thorac Imaging. 2001;16(1):35-46.

52. Liu Q, Lu JP, Wang F, Wang L, Tian JM. Three-dimensional contrast-enhanced MR angiography of aortic dissection: a pic-torial essay. Radiographics. 2007;27(5):1311-1321.

53. Miller DC, Mitchell RS, Oyer PE, Stinson EB, Jamieson SW, Shumway NE. Independent determinants of operative mortality for patients with aortic dissections. Circulation. 1984;70(3, pt 2):I153-I164.

54. Estrera AL, Huynh TT, Porat EE, Miller CC III, Smith JJ, Safi HJ. Is acute type A aortic dissection a true surgical emergency? Semin Vasc Surg. 2002;15(2):75-82.

55. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001;345(5):351-358.

56. McCord J, Jneid H, Hollander JE, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the american heart association acute cardiac care committee of the council on clinical cardiology. Circulation. 2008;117(14):1897-1907.

57. Neri E, Toscano T, Massetti M, et al. Operation for acute type A aortic dissection in octogenarians: is it justified? J Thorac Cardiovasc Surg. 2001;121(2):259-267.

58. Fann JI, Sarris GE, Miller DC, et al. Surgical management of acute aortic dissection complicated by stroke. Circulation. 1989;80(3, pt 1):I257-1263.

59. Svensson LG, Kouchoukos NT, Miller DC, et al. Expert con-sensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. Ann Thorac Surg. 2008;85(suppl 1):S1-S41.

60. Kwolek CJ, Watkins MT. The INvestigation of STEnt grafts in aortic dissection (INSTEAD) trial: the need for ongoing analy-sis. Circulation. 2009;120(25):2513-2514.

61. Lombardi JV, Cambria RP, Nienaber CA, et al. Prospective mul-ticenter clinical trial (STABLE) on the endovascular treatment of complicated type B aortic dissection using a composite device design. J Vasc Surg. 2012;55(3):629.e2-640.e2.


References 3

62. Bachet J. Acute type A aortic dissection: can we dramatically reduce the surgical mortality? Ann Thorac Surg. 2002;73(3): 701-703.

63. Graham JM, Stinnett DM. Operative management of acute aor-tic arch dissection using profound hypothermia and circulatory arrest. Ann Thorac Surg. 1987;44(2):192-198.

64. Bachet J, Guilmet D, Goudot B, et al. Cold cerebroplegia. A new technique of cerebral protection during operations on the trans-verse aortic arch. J Thorac Cardiovasc Surg. 1991;102(1):85-93; discussion 93-94.

65. Bachet J, Teodori G, Goudot B, et al. Replacement of the trans-verse aortic arch during emergency operations for type A acute aortic dissection. report of 26 cases. J Thorac Cardiovasc Surg. 1988;96(6):878-886.

66. Deville C, Roques X, Fernandez G, Laborde N, Baudet E, Fontan F. Should circulatory arrest with deep hypothermia be revised in aortic arch surgery? Eur J Cardiothorac Surg. 1988;2(3):185-191.

67. Coselli JS. Retrograde cerebral perfusion via a superior vena caval cannula for aortic arch aneurysm operations. Ann Thorac Surg. 1994;57(6):1668-1669.

68. Bavaria JE, Woo YJ, Hall RA, Wahl PM, Acker MA, Gardner TJ. Circulatory management with retrograde cerebral perfusion for acute type A aortic dissection. Circulation. 1996;94(suppl 9):II173-II176.

69. Koster JK Jr, Cohn LH, Mee RB, Collins JJ Jr. Late results of operation for acute aortic dissection producing aortic insuf-ficiency. Ann Thorac Surg. 1978;26(5):461-467.

70. Crawford ES, Coselli JS, Svensson LG, Safi HJ, Hess KR. Diffuse aneurysmal disease (chronic aortic dissection, marfan, and mega aorta syndromes) and multiple aneurysm. treatment by subtotal and total aortic replacement emphasizing the elephant trunk operation. Ann Surg. 1990;211(5):521-537.

71. Crawford ES, Svensson LG, Hess KR, et al. A prospective randomized study of cerebrospinal fluid drainage to prevent paraplegia after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg. 1991;13(1):36-45; discussion 45-46.

72. Borst HG, Jurmann M, Buhner B, Laas J. Risk of replacement of descending aorta with a standardized left heart bypass tech-nique. J Thorac Cardiovasc Surg. 1994;107(1):126-132; discus-sion 132-133.

73. Safi HJ, Bartoli S, Hess KR, et al. Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: the role of cerebral spinal fluid drainage and distal aortic perfusion. J Vasc Surg. 1994;20(3):434-444; discussion 442-443.

74. Jex RK, Schaff HV, Piehler JM, et al. Early and late results fol-lowing repair of dissections of the descending thoracic aorta. J Vasc Surg. 1986;3(2):226-237.

75. Luciani GB, Mazzucco A. Aortic insufficiency after surgical repair of acute type a aortic dissection: incidence, indications for reoperation and medical management. J Heart Valve Dis. 2001;10(1):12-18.

76. Parker JD, Golledge J. Outcome of endovascular treatment of acute type B aortic dissection. Ann Thorac Surg. 2008;86(5): 1707-1712.

77. Doroghazi RM, Slater EE, DeSanctis RW, Buckley MJ, Austen WG, Rosenthal S. Long-term survival of patients with treated aortic dissection. J Am Coll Cardiol. 1984;3(4):1026-1034.

78. DeBakey ME, McCollum CH, Crawford ES, et al. Dissection and dissecting aneurysms of the aorta: twenty-year follow-up of five hundred twenty-seven patients treated surgically. Surgery. 1982;92(6):1118-1134.

79. Nordon IM, Hinchliffe RJ, Loftus IM, Morgan RA, Thompson MM. Management of acute aortic syndrome and chronic aortic dissection. Cardiovasc Intervent Radiol. 2011;34(5):890-902.

80. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73(1):17-27; discussion 27-28.

81. Januzzi JL, Movsowitz HD, Choi J, Abernethy WB, Isselbacher EM. Significance of recurrent pain in acute type B aortic dissec-tion. Am J Cardiol. 2001;87(7):930-933.


Chapter 31 · Chapter 31 REFERENCES 1. Guyton AC. ... 33.Vary TC. Increased pyruvate ......

Documents

Transcript of Chapter 31 · Chapter 31 REFERENCES 1. Guyton AC. ... 33.Vary TC. Increased pyruvate ......